

Description

Title of Invention: ASYMMETRIC AUXILIARY GROUP

FIELD OF THE INVENTION

[0001] The present invention is directed to a chiral reagent that is used to synthesize stereo-controlled phosphorus atom-modified oligonucleotide derivatives.

BACKGROUND OF THE INVENTION

[0002] JP 2005-89441 A discloses a method for producing a derivative of nucleotides called an oxazaphospholidine method. However, the isolate yield of the monomers is low and the method requires special capping agents that are not commercially available. Further obtained monomers are chemically unstable. Furthermore, the isolate yields of oligonucleotide derivatives are not high. It is thought that the low yield of oligonucleotide derivatives is caused by the degradation reactions under the de-protection steps.

[0003] WO2010/064146 pamphlet discloses a method for producing a derivative of nucleotides. The method disclosed therein requires special capping agents that are not commercially available. Furthermore, the isolate yields of oligonucleotide derivatives are not high. The low yield is thought to be caused by the degradation reactions under the de-protection steps. This tendency becomes strongly apparent when the length of oligonucleotide derivatives becomes long.

[0004] WO2012/039448 pamphlet discloses Asymmetric auxiliary group which is used to produce stereocontrolled phosphorus atom-modified oligonucleotide derivatives.

Citation List


Patent Literature

[0005] [Patent Literature 1] JP 2005-89441 A
 [Patent Literature 2] WO2010/064146 A
 [Patent Literature 3] WO2012/039448 A

SUMMARY OF THE INVENTION

[0006] The first Aspect of the Invention relates to a chiral reagent or a salt thereof. The chiral reagent has following chemical formula (I).


[0007]



[0008] In the formula (I), G¹ and G² are independently a hydrogen atom, a nitro group (-NO₂), a halogen atom, a cyano group (-CN), a group of formula (II), (III) or (V), or both G¹


and G² taken together to form a group of formula (IV).

[0009]




[0010] In the formula (II), G²¹ to G²³ are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C₁₋₃ alkyl group.

[0011]




[0012] In the formula (III), G³¹ to G³³ are independently C₁₋₄ alkyl group, C₆₋₁₄ aryl group, C₁₋₄ alkoxy group, C₇₋₁₄ aralkyl group, C₁₋₄ alkyl C₆₋₁₄ aryl group, C₁₋₄ alkoxy C₆₋₁₄ aryl group, or C₆₋₁₄ aryl C₁₋₄ alkyl group.

[0013]



[0014] In the formula (IV), G⁴¹ to G⁴⁶ are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C₁₋₃ alkyl group.

[0015]




[0016] In the formula (V), G⁵¹ to G⁵³ are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, C₁₋₃ alkyl group or C₁₋₃ alkyloxy group.

[0017] G³ and G⁴ are independently a hydrogen atom, C₁₋₃ alkyl group, C₆₋₁₄ aryl group, or both G³ and G⁴ taken together to form a heteroatom-containing ring that has 3 to 16

carbon atoms, together with the NH moiety in formula (I).

[0018] A preferred embodiment is that the chiral reagent has following chemical formula (I').

[0019]



[0020] In the formula (I'), G¹ and G² are same as above. Namely, G¹ and G² are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, a group of formula (II) or (III), or both G¹ and G² taken together to form a group of formula (IV).

[0021] A preferred embodiment is that the chiral reagent has chemical formula (I') and each of G¹ and G² is a group of formula (II), wherein G²¹ to G²³ are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C₁₋₃ alkyl group.

[0022] A preferred embodiment is that the chiral reagent has chemical formula (I') and each of G¹ and G² is a group of formula (II) and each of G²¹ to G²³ is a hydrogen atom

[0023] A preferred embodiment is that the chiral reagent has chemical formula (I') and G¹ is a hydrogen atom, G² is a group of formula (II), and G²¹ to G²³ are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C₁₋₃ alkyl group.

[0024] A preferred embodiment is that the chiral reagent has chemical formula (I') and G¹ is a hydrogen atom, G² is a group of formula (II), each of G²¹ and G²² is a hydrogen atom and G²³ is a nitro group.

[0025] A preferred embodiment is that the chiral reagent has chemical formula (I') and G¹ is a hydrogen atom and G² is a group of formula (III), and G³¹ to G³³ are independently C₁₋₄ alkyl group, C₆₋₁₄ aryl group, C₇₋₁₄ aralkyl group, C₁₋₄ alkyl C₆₋₁₄ aryl group, C₁₋₄ alkoxy C₆₋₁₄ aryl group, or C₆₋₁₄ aryl C₁₋₄ alkyl group.

[0026] A preferred embodiment is that the chiral reagent has chemical formula (I') and G¹ is a hydrogen atom and G² is a group of formula (III), and G³¹ to G³³ are independently C₁₋₄ alkyl group, C₆ aryl group, C₇₋₁₀ aralkyl group, C₁₋₄ alkyl C₆ aryl group, C₁₋₄ alkoxy C₆ aryl group, or C₆ aryl C₁₋₄ alkyl group.

[0027] A preferred embodiment is that the chiral reagent has chemical formula (I') and G¹ is a hydrogen atom, G² is a group of formula (III), and G³¹ to G³³ are independently C₁₋₄ alkyl group or C₆ aryl group. Examples of C₁₋₄ alkyl group are methyl group, ethyl group, n-propyl group, iso-propyl group, n-buthyl group and tert-buthyl group.

[0028] A preferred embodiment is that the chiral reagent has chemical formula (I') and G¹ is a hydrogen atom, G² is a group of formula (III), and G³¹ to G³³ are independently C₁₋₄ alkyl group.

[0029] A preferred embodiment is that the chiral reagent has chemical formula (I') and G¹ is

a hydrogen atom, G^2 is a group of formula (III), and G^{31} and G^{33} are C_6 aryl group and G^{32} is C_{1-4} alkyl group.

[0030] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 and G^2 taken together to form a group of formula (IV), and G^{41} to G^{46} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-4} alkyl group.

[0031] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 and G^2 taken together to form a group of formula (IV), wherein each of G^{41} to G^{46} is a hydrogen atom.

[0032] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 is a hydrogen atom and G^2 is a group of formula (V). Further each of G^{51} to G^{53} is independently a hydrogen atom, a nitro group, a methyl group, or a methoxy group. More preferred embodiment is that G^1 is a hydrogen atom and G^2 is a group of formula (V), wherein each of G^{51} and G^{53} is a hydrogen atom and G^{52} is a 4-methyl group.

[0033] A preferred embodiment is that the chiral reagent is selected from one of III-a, III-b, V-a, VII-a, VII-b, IX-a, IX-b, XI-a, XIII-a and XIII-b::

(S)-2-(Methyldiphenylsilyl)-1-((S)-pyrrolidin-2-yl)ethanol (III-a)

(R)-2-(Methyldiphenylsilyl)-1-((R)-1-pyrrolidin-2-yl)ethanol (III-b)

(S)-2-(Trimethylsilyl)-1-((S)-1-pyrrolidin-2-yl)ethanol (V-a)

(R)-2,2-Diphenyl-1-((S)-pyrrolidin-2-yl)ethanol (VII-a)

(S)-2,2-Diphenyl-1-((R)-pyrrolidin-2-yl)ethanol (VII-b)

(R)-2-(4-Nitrophenyl)-1-((S)-pyrrolidin-2-yl)ethanol (IX-a)

(S)-2-(4-Nitrophenyl)-1-((R)-pyrrolidin-2-yl)ethanol (IX-b)



(R)-(9H-Fluorenyl)-1-((S)-pyrrolidin-2-yl)methanol (XI-a)

(S)-2-Tosyl-1-((S)-1-tritylpyrrolidin-2-yl)ethanol (XIII-a)

(R)-2-Tosyl-1-((R)-1-tritylpyrrolidin-2-yl)ethanol (XIII-b)


[0034] The second aspect of the invention relates to a nucleoside 3'-phosphoramidite derivative which is represented by formula (Va) or (Vb).

[0035]




[0036] In the formula (Va) and (Vb), G^1 to G^4 are same as above, G^5 is a protective group of the hydroxyl group, and Bs is a group selected from the groups represented by following formula (VI) to (XI) or derivatives thereof.


[0037]




(VI)




(VII)




(VIII)



(IX)



(X)



(XI)

[0038] Examples of Bs are an adenine, a thymine, a cytosine, a guanine, an uracil, a 5-methylcytosine or derivative thereof.

[0039] R^2 is hydrogen, -OH, -SH, $-NR^dR^d$, $-N_3$, halogen, alkyl, alkenyl, alkynyl, alkyl- Y^1 -, alkenyl- Y^1 -, alkynyl- Y^1 -, aryl- Y^1 -, heteroaryl- Y^1 -, $-OR^b$, or $-SR^b$, wherein R^b is a blocking moiety.

Y^1 is O, NR^d , S, or Se.

R^d is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, $-P(O)(R^e)_2$, or $-HP(O)(R^e)$.

R^e is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl- Y^2 -, alkenyl- Y^2 -, alkynyl- Y^2 -, aryl- Y^2 -, or heteroaryl- Y^2 -, or a cation which is Na^+ , Li^+ , or K^+ .



Y^2 is O, NR^d , or S.

[0040] R^3 is a group represented by $-CH_2-$, $-(CH_2)_2-$, $-CH_2NH-$, or $-CH_2N(CH_3)-$.

[0041] Examples of G^5 are trityl, 4-monomethoxytrityl, 4,4'-dimethoxytrityl, 4,4',4''-trimethoxytrityl, 9-phenylxanthin-9-yl (Pixyl) and 9-(p-methoxyphenyl)xanthin-9-yl (MOX).

[0042] A preferred embodiment of the second aspect is that the nucleoside 3'-phosphoramidite derivative is represented by formula (Va') or (Vb').

[0043]



[0044] In the formula (Va') and (Vb'), G¹, G², G⁵, Bs, R², and R³ are same as above.

[0045] The third aspect of the invention relates to a method for synthesis of a stereo-controlled phosphorus atom-modified oligonucleotide derivative.

[0046] First step is a step of reacting a molecule comprising an achiral H-phosphonate moiety, the first activating reagent and a chiral reagent or a salt thereof to form a monomer. The chiral reagent has chemical formula (I) or (I') and the monomer may be represented by formula (Va), (Vb), (Va'), or (Vb'). The monomer reacts with the second activating reagent and a nucleoside to form a condensed intermediate. Next step is a step of converting the condensed intermediate to the nucleic acid comprising a chiral X-phosphonate moiety.

[0047] Based on the present method, it is possible to use stable and commercially available materials as starting materials. It is possible to produce stereocontrolled phosphorus atom-modified oligonucleotide derivatives using an achiral starting material.

[0048] As shown in a working example, the method of the present invention does not cause degradations under de-protection steps. Further the method does not require special capping agents to produce phosphorus atom-modified oligonucleotide derivatives.

[0049] The fourth aspect of the invention relates to a method for synthesis of stereo-controlled phosphorus atom-modified oligonucleotide derivatives using a chiral monomer.

[0050] The first step is reacting a nucleoside 3'-phosphoramidite derivative which is represented by formula (Va), (Vb), (Va'), or (Vb') with the second activating reagent and a nucleoside to form a condensed intermediate. The second step is converting the condensed intermediate to the nucleic acid comprising a chiral X-phosphonate moiety.

INCORPORATION BY REFERENCE

[0051] All publications and patent applications disclosed herein in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Brief Description of Drawings

[0052] [fig.1]Figure 1 is UPLC profile in producing oligonucleotide derivative using the monomer of 4b.

[fig.2]Figure 2 is UPLC profile in producing oligonucleotide derivative using the monomer of 25.

Best Mode for Carrying out the Invention

[0053] The term "nucleic acid" encompasses poly- or oligo-ribonucleotides (RNA) and poly- or oligo-deoxyribonucleotides (DNA); RNA or DNA derived from N-glycosides or C-glycosides of nucleobases and/or modified nucleobases; nucleic acids derived from sugars and/or modified sugars; and nucleic acids derived from phosphate bridges and/or modified phosphorus-atom bridges. The term encompasses nucleic acids containing any combinations of nucleobases, modified nucleobases, sugars, modified sugars, phosphate bridges or modified phosphorus atom bridges. Examples include, and are not limited to, nucleic acids containing ribose moieties, the nucleic acids containing deoxyribose moieties, nucleic acids containing both ribose and deoxyribose moieties, nucleic acids containing ribose and modified ribose moieties. The prefix poly- refers to a nucleic acid containing about 1 to about 10,000 nucleotide monomer units and wherein the prefix oligo- refers to a nucleic acid containing about 1 to about 200 nucleotide monomer units.

[0054] The term "nucleobase" refers to the parts of nucleic acids that are involved in the hydrogen-bonding that binds one nucleic acid strand to another complementary strand in a sequence specific manner. The most common naturally-occurring nucleobases are adenine (A), guanine (G), uracil (U), cytosine (C), 5-methylcytosine, and thymine (T).

[0055] The term "modified nucleobase" refers to a moiety that can replace a nucleobase. The modified nucleobase mimics the spatial arrangement, electronic properties, or some other physicochemical property of the nucleobase and retains the property of hydrogen-bonding that binds one nucleic acid strand to another in a sequence specific manner. A modified nucleobase can pair with all of the five naturally occurring bases (uracil, thymine, adenine, cytosine, or guanine) without substantially affecting the melting behaviour, recognition by intracellular enzymes or activity of the oligonucleotide duplex.

[0056] The term "nucleoside" refers to a moiety wherein a nucleobase or a modified nucleobase is covalently bound to a sugar or modified sugar.

[0057] The term "sugar" refers to a monosaccharide in closed and/or open form. Sugars include, but are not limited to, ribose, deoxyribose, pentofuranose, pentopyranose, and hexopyranose moieties.

[0058] The term "modified sugar" refers to a moiety that can replace a sugar. The modified

sugar mimics the spatial arrangement, electronic properties, or some other physico-chemical property of a sugar.

- [0059] The term "nucleotide" refers to a moiety wherein a nucleobase or a modified nucleobase is covalently linked to a sugar or modified sugar, and the sugar or modified sugar is covalently linked to a phosphate group or a modified phosphorus-atom moiety.
- [0060] The term "chiral reagent" refers to a compound that is chiral or enantiopure and can be used for asymmetric induction in nucleic acid synthesis.
- [0061] The term "chiral ligand" or "chiral auxiliary" refers to a moiety that is chiral or enantiopure and controls the stereochemical outcome of a reaction.
- [0062] In a condensation reaction, the term "activating reagent" refers to a reagent that activates a less reactive site and renders it more susceptible to attack by a nucleophile.
- [0063] The term "blocking moiety" refers to a group that transiently masks the reactivity of a functional group. The functional group can be subsequently unmasked by removal of the blocking moiety.
- [0064] The terms "boronating agents", "sulfur electrophiles", "selenium electrophiles" refer to compounds that are useful in the modifying step used to introduce BH_3 , S, and Se groups, respectively, for modification at the phosphorus atom.
- [0065] The term "moiety" refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule.
- [0066] The term "solid support" refers to any support which enables synthetic mass production of nucleic acids and can be reutilized at need. As used herein, the term refers to a polymer that is insoluble in the media employed in the reaction steps performed to synthesize nucleic acids, and is derivatized to comprise reactive groups.
- [0067] The term "linking moiety" refers to any moiety optionally positioned between the terminal nucleoside and the solid support or between the terminal nucleoside and another nucleoside, nucleotide, or nucleic acid.
- [0068] As used herein, "treatment" or "treating," or "palliating" or "ameliorating" are used interchangeably herein. These terms refers to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. For prophylactic benefit, the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.

- [0069] A "therapeutic effect," as that term is used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
- [0070] An "alkyl" group refers to an aliphatic hydrocarbon group. The alkyl moiety may be a saturated alkyl group (which means that it does not contain any units of unsaturation, e.g. carbon-carbon double bonds or carbon-carbon triple bonds) or the alkyl moiety may be an unsaturated alkyl group (which means that it contains at least one unit of unsaturation). The alkyl moiety, whether saturated or unsaturated, may be branched, straight chain, or include a cyclic portion. The point of attachment of an alkyl is at a carbon atom that is not part of a ring.
- [0071] The "alkyl" moiety may have 1 to 10 carbon atoms (whenever it appears herein, a numerical range such as "1 to 10" refers to each integer in the given range; e.g., "1 to 10 carbon atoms" means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although the present definition also covers the occurrence of the term "alkyl" where no numerical range is designated). Alkyl includes both branched and straight chain alkyl groups. The alkyl group of the compounds described herein may be designated as "C₁-C₆ alkyl" or similar designations. By way of example only, "C₁-C₆ alkyl" indicates that there are one, two, three, four, five, or six carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, allyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, and the like. In one aspect, an alkyl is a C₁-C₆ alkyl.
- [0072] C₁₋₃ alkyl group means straight or branched alkyl group that has 1 to 3 carbon atoms. Examples of C₁₋₃ alkyl group are methyl, ethyl, propyl and isopropyl. C₁₋₄ alkyl group means straight or branched alkyl group that has 1 to 4 carbon atoms. Examples of C₁₋₄ alkyl group are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
- [0073] As used herein, the term "aryl" refers to an aromatic ring wherein each of the atoms forming the ring is a carbon atom. Aryl rings are formed by five, six, seven, eight, nine, or more than nine carbon atoms. Aryl groups are a substituted or unsubstituted. In one aspect, an aryl is a phenyl or a naphthalenyl. Depending on the structure, an aryl group can be a monoradical or a diradical (i.e., an arylene group). In one aspect, an aryl is a C₆-C₁₀ aryl.
- [0074] C₆₋₁₄ aryl group means aryl group that has 6 to 14 carbon atoms. The examples of C₆₋₁₄ aryl group are phenyl, biphenyl, naphthyl, anthracyl, indanyl, phthalimidyl, naph-

thimidyl, phenanthridinyl, and tetrahydronaphthyl.

- [0075] The term "aralkyl" refers to an alkyl group substituted with an aryl group. Suitable aralkyl groups include benzyl, picolyl, and the like, all of which may be optionally substituted.
- [0076] An "acyl moiety" refers to an alkyl(C=O), aryl(C=O), or aralkyl(C=O) group. An acyl moiety can have an intervening moiety (Y) that is oxy, amino, thio, or seleno between the carbonyl and the hydrocarbon group. For example, an acyl group can be alkyl-Y-(C=O), aryl-Y-(C=O) or aralkyl-Y-(C=O).
- [0077] "Alkenyl" groups are straight chain, branch chain, and cyclic hydrocarbon groups containing at least one carbon-carbon double bond. Alkenyl groups can be substituted.
- [0078] "Alkynyl" groups are straight chain, branch chain, and cyclic hydrocarbon groups containing at least one carbon-carbon triple bond. Alkynyl groups can be substituted.
- [0079] An "alkoxy" group refers to an alkyl group linked to oxygen i.e. (alkyl)-O- group, where alkyl is as defined herein. Examples include methoxy (-OCH₃) or ethoxy (-OCH₂CH₃) groups.
- [0080] An "alkenyloxy" group refers to an alkenyl group linked to oxygen i.e. (alkenyl)-O- group, where alkenyl is as defined herein.
- [0081] An "alkynyloxy" group refers to an alkynyl group linked to oxygen i.e. (alkynyl)-O- group, where alkynyl is as defined herein.
- [0082] An "aryloxy" group refers to an aryl group linked to oxygen i.e. (aryl)-O- group, where the aryl is as defined herein. An example includes phenoxy (-OC₆H₅) group.
- [0083] The term "alkylseleno" refers to an alkyl group having a substituted seleno group attached thereto i.e. (alkyl)-Se- group, wherein alkyl is defined herein.
- [0084] The term "alkenylseleno" refers to an alkenyl group having a substituted seleno group attached thereto i.e. (alkenyl)-Se- group, wherein alkenyl is defined herein.
- [0085] The term "alkynylseleno" refers to an alkynyl group having a substituted seleno group attached thereto i.e. (alkynyl)-Se- group, wherein alkenyl is defined herein.
- [0086] The term "alkylthio" refers to an alkyl group attached to a bridging sulfur atom i.e. (alkyl)-S- group, wherein alkyl is defined herein. For example, an alkylthio is a methylthio and the like.
- [0087] The term "alkenylthio" refers to an alkenyl group attached to a bridging sulfur atom i.e. (alkenyl)-S- group, wherein alkenyl is defined herein.
- [0088] The term "alkynylthio" refers to an alkynyl group attached to a bridging sulfur atom i.e. (alkynyl)-S- group, wherein alkenyl is defined herein.
- [0089] The term "alkylamino" refers to an amino group substituted with at least one alkyl group i.e. -NH(alkyl) or -N(alkyl)₂, wherein alkyl is defined herein.
- [0090] The term "alkenylamino" refers to an amino group substituted with at least one alkenyl group i.e. -NH(alkenyl) or -N(alkenyl)₂, wherein alkenyl is defined herein.

- [0091] The term "alkynylamino" refers to an amino group substituted with at least one alkynyl group i.e. -NH(alkynyl) or -N(alkynyl)₂, wherein alkynyl is defined herein.
- [0092] The term "halogen" is intended to include fluorine, chlorine, bromine and iodine.
- [0093] A "fluorescent group" refers to a molecule that, when excited with light having a selected wavelength, emits light of a different wavelength. Fluorescent groups include, but are not limited to, indole groups, fluorescein, tetramethylrhodamine, Texas Red, BODIPY, 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS), coumarin and Lucifer yellow.
- [0094] An "ammonium ion" is a positively charged polyatomic cation of the chemical formula NH₄⁺.
- [0095] An "alkylammonium ion" is an ammonium ion that has at least one of its hydrogen atoms replaced by an alkyl group, wherein alkyl is defined herein. Examples include triethylammonium ion, N,N-diisopropylethylammonium ion.
- [0096] An "iminium ion" has the general structure R₂C=NR₂⁺. The R groups refer to alkyl, alkenyl, alkynyl, aryl groups as defined herein. A "heteroaromatic iminium ion" refers to an iminium ion where the nitrogen and its attached R groups form a heteroaromatic ring. A "heterocyclic iminium ion" refers to an iminium ion where the nitrogen and its attached R groups form a heterocyclic ring.
- [0097] The terms "amino" or "amine" refers to a -N(R^h)₂ radical group, where each R^h is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, unless stated otherwise specifically in the specification. When a -N(R^h)₂ group has two R^h other than hydrogen they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, -N(R^h)₂ is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl. Any one or more of the hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl are optionally substituted by one or more substituents which independently are alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilyl, -ORⁱ, -SRⁱ, -OC(O)Rⁱ, -N(Rⁱ)₂, -C(O)Rⁱ, -C(O)ORⁱ, -OC(O)N(Rⁱ)₂, -C(O)N(Rⁱ)₂, -N(Rⁱ)C(O)OR, -N(Rⁱ)C(O)Rⁱ, -N(Rⁱ)C(O)N(Rⁱ)₂, N(Rⁱ)C(NRⁱ)N(Rⁱ)₂, -N(Rⁱ)S(O)_tRⁱ (where t is 1 or 2), -S(O), or -S(O)_tN(Rⁱ)₂ (where t is 1 or 2), where each Rⁱ is independently hydrogen, alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl.
- [0098] "Carbamate" as used herein, refers to a moiety attached to an amino group which has the formula -C(O)OR where R is alkyl, fluoroalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl. Examples include but are not limited to Boc (tert-butyl-OC(O)-), CBz (benzyl-OC(O)-), Teoc


(Me₃SiCH₂CH₂OC(O)-), alloc (allyl-OC(O)-), or Fmoc (9-fluorenylmethyl-OC(O)-) group.

[0099] "Substituted silyl" as used herein, refers to a moiety which has the formula R₃Si-. Examples include, but are not limited to, TBDMS (tert-butyldimethylsilyl), TBDPS (tert-butyldiphenylsilyl) or TMS (trimethylsilyl) group.

[0100] The term "thiol" refers to -SH groups, and include substituted thiol groups i.e. -SR^J groups, wherein R^J are each independently a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl alkyl, heterocyclyl or heterocyclalkyl group as defined herein.


[0101] The first aspect of the invention relates to a chiral reagent or a salt thereof. The chiral reagent has following chemical formula (I). The term "chiral reagent" is a chemical composition which is used to produce stereocontrolled phosphorus atom-modified nucleotide or oligonucleotide derivatives. The chiral reagent reacts with a nucleotide to form a chiral intermediate.

[0102]




[0103] In the formula (I), G¹ and G² are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group (-CN), a group of formula (II), (III) or (V), or both G¹ and G² taken together to form a group of formula (IV).

[0104]



[0105] In the formula (II), G²¹ to G²³ are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C₁₋₃ alkyl group. Preferred examples of G²¹ to G²³ are a hydrogen atom.


[0106]



[0107] In the formula (III), G³¹ to G³³ are independently C₁₋₄ alkyl group, C₆₋₁₄ aryl group, C₁₋₄ alkoxy group, C₇₋₁₄ aralkyl group, C₁₋₄ alkyl C₆₋₁₄ aryl group, C₁₋₄ alkoxy C₆₋₁₄ aryl group, or C₆₋₁₄ aryl C₁₋₄ alkyl group. Examples of C₁₋₄ alkyl C₆₋₁₄ aryl group are


methylphenyl group, and ethylphenyl group. Examples of C_{1-4} alkoxy C_{6-14} aryl group are a methoxyphenyl group and an ethoxyphenyl group. Examples of C_{6-14} aryl C_{1-4} alkyl groups are a benzyl group and a phenylethyl group. Preferred examples of G^{31} to G^{33} are independently a methyl group and a phenyl group.

[0108]



[0109] In the formula (IV), G^{41} to G^{46} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group. Preferred examples of G^{41} to G^{46} are a hydrogen atom.

[0110]




[0111] In the formula (V), G^{51} to G^{53} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, C_{1-3} alkyl group or C_{1-3} alkyloxy group.

[0112] G^3 and G^4 are independently a hydrogen atom, C_{1-3} alkyl group, C_{6-14} aryl group, or both G^3 and G^4 taken together to form a heteroatom-containing ring that has 3 to 16 carbon atoms. Preferred examples of G^3 and G^4 are that taken together to form a heteroatom-containing ring that has 3 to 16 carbon atoms with NH moiety in the formula (I).

[0113] A preferred embodiment is that the chiral reagent has following chemical formula (I').

[0114]



[0115] In the formula (I'), G^1 and G^2 are same as above and G^1 and G^2 are independently a

hydrogen atom, a nitro group, a halogen atom, a cyano group, a group of formula (II) or (III), or both G^1 and G^2 taken together to form a group of formula (IV).

- [0116] A preferred embodiment is that the chiral reagent has chemical formula (I') and each of G^1 and G^2 is a group of formula (II), wherein G^{21} to G^{23} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group.
- [0117] A preferred embodiment is that the chiral reagent has chemical formula (I') and each of G^1 and G^2 is a group of formula (II) and each of G^{21} to G^{23} is a hydrogen atom.
- [0118] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 is a hydrogen atom, G^2 is a group of formula (II), and G^{21} to G^{23} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group.
- [0119] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 is a hydrogen atom, G^2 is a group of formula (II), each of G^{21} and G^{22} is a hydrogen atom and G^{23} is a nitro group ($-\text{NO}_2$).
- [0120] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 is a hydrogen atom and G^2 is a group of formula (III), and G^{31} to G^{33} are independently C_{1-4} alkyl group, C_{6-14} aryl group, C_{7-14} aralkyl group, C_{1-4} alkyl C_{6-14} aryl group, C_{1-4} alkoxy C_{6-14} aryl group, or C_{6-14} aryl C_{1-4} alkyl group.
- [0121] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 is a hydrogen atom and G^2 is a group of formula (III), and G^{31} to G^{33} are independently C_{1-4} alkyl group, C_6 aryl group, C_{7-10} aralkyl group, C_{1-4} alkyl C_6 aryl group, C_{1-4} alkoxy C_6 aryl group, or C_6 aryl C_{1-4} alkyl group.
- [0122] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 is a hydrogen atom, G^2 is a group of formula (III), and G^{31} to G^{33} are independently C_{1-4} alkyl group or C_6 aryl group (a phenyl group). Examples of C_{1-4} alkyl group are methyl group, ethyl group, n-propyl group, iso-propyl group, n-butyl group and tert-butyl group.
- [0123] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 is a hydrogen atom, G^2 is a group of formula (III), and G^{31} to G^{33} are independently C_{1-4} alkyl group.
- [0124] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 is a hydrogen atom, G^2 is a group of formula (III), and G^{31} and G^{33} are C_6 aryl group (a phenyl group) and G^{32} is C_{1-2} alkyl group.
- [0125] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 and G^2 taken together to form a group of formula (IV), and G^{41} to G^{46} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group.
- [0126] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 and G^2 taken together to form a group of formula (IV), wherein each of G^{41} to G^{46} is a

hydrogen atom.

[0127] A preferred embodiment is that the chiral reagent has chemical formula (I') and G^1 is a hydrogen atom and G^2 is a group of formula (V). Further each of G^{51} to G^{53} is independently a hydrogen atom, a nitro group, a methyl group, or a methoxy group. More preferred embodiment is that G^1 is a hydrogen atom and G^2 is a group of formula (V), wherein each of G^{51} and G^{53} is a hydrogen atom and G^{52} is a 4-methyl group.

[0128] A preferred embodiment is that the chiral reagent is selected from one of III-a, III-b, V-a, VII-a, VII-b, IX-a, IX-b, XI-a, XIII-a and XIII-b:

(S)-2-(Methyldiphenylsilyl)-1-((S)-pyrrolidin-2-yl)ethanol (III-a)

(R)-2-(Methyldiphenylsilyl)-1-((R)-1-pyrrolidin-2-yl)ethanol (III-b)

(S)-2-(Trimethylsilyl)-1-((S)-1-pyrrolidin-2-yl)ethanol (V-a)

(R)-2,2-Diphenyl-1-((S)-pyrrolidin-2-yl)ethanol (VII-a)

(S)-2,2-Diphenyl-1-((R)-pyrrolidin-2-yl)ethanol (VII-b)

(R)-2-(4-Nitrophenyl)-1-((S)-pyrrolidin-2-yl)ethanol (IX-a)

(S)-2-(4-Nitrophenyl)-1-((R)-pyrrolidin-2-yl)ethanol (IX-b)

(R)-(9H-Fluorenyl)-1-((S)-pyrrolidin-2-yl)methanol (XI-a)



(S)-2-Tosyl-1-((S)-1-tritylpyrrolidin-2-yl)ethanol (XIII-a)

(R)-2-Tosyl-1-((R)-1-tritylpyrrolidin-2-yl)ethanol (XIII-b)

[0129] The chiral reagent reacts with a nucleic acid or modified nucleic acid to be an asymmetric auxiliary group. A nucleoside 3'-phosphoramidite derivative, which is an intermediate of manufacturing a stereocontrolled phosphorus atom-modified oligonucleotide derivative, is obtained by chiral reagent reacting with a nucleic acid or modified nucleic acid.


[0130] The second aspect of the invention relates to a nucleoside 3'-phosphoramidite derivative which is represented by formula (Va) or (Vb). The compounds of formula (Va) and (Vb) are known as monomers that are used in synthesizing oligonucleotide derivatives. These compounds are also known as oxazaphospholidine monomers. The sugar moieties of the compounds represented by formula (Vb) are known as BNA and LNA (when R^3 is a methylene group).

[0131]



[0132] In the formula (Va) and (Vb), G^1 to G^4 are same as above, G^5 is a protective group of the hydroxyl group, and Bs is a group selected from the groups represented by formula (VI) to (XI) or derivatives thereof.

[0133]



[0134] Examples of Bs are an adenine, a thymine, a cytosine, a guanine, an uracil, a 5-methylcytosine, or derivative thereof.

[0135] R^2 is hydrogen, -OH, -SH, $-NR^dR^d$, $-N_3$, halogen, alkyl, alkenyl, alkynyl, alkyl- Y^1 -, alkenyl- Y^1 -, alkynyl- Y^1 -, aryl- Y^1 -, heteroaryl- Y^1 -, $-OR^b$, or $-SR^b$, wherein R^b is a blocking moiety.

Y^1 is O, NR^d , S, or Se.

R^d is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, $-P(O)(R^e)_2$, or $-HP(O)(R^e)$.

R^e is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl- Y^2 -, alkenyl- Y^2 -, alkynyl- Y^2 -, aryl- Y^2 -, or heteroaryl- Y^2 -, or a cation which is Na^+ , Li^+ , or K^+ .

Y^2 is O, NR^d , or S.

Preferred examples of alkyl are C_{1-10} alkyl group, preferred examples of alkenyl are C_{2-10} alkenyl, preferred examples of alkynyl are C_{2-10} alkynyl, preferred examples of aryl are C_{6-14} aryl, and preferred examples of heteroaryl are C_{6-14} heteroaryl.


[0136] R^3 is a group represented by $-CH_2-$, $-(CH_2)_2-$, $-CH_2NH-$, or $-CH_2N(CH_3)-$.

[0137] Examples of G^5 the trityl, 4-monomethoxytrityl, 4,4'-dimethoxytrityl, 4,4',4''-trimethoxytrityl, 9-phenylxanthin-9-yl (Pixyl) and 9-(p-methoxyphenyl)xanthin-9-yl (MOX).

[0138] Bs is an adenine, a thymine, a cytosine, a guanine, or derivative thereof. Bs is a nucleobase or a modified nucleobase. The examples of the derivatives are that disclosed

in JP 2005-89441 A and are represented as follows.


[0139]



[0140] In the above formula, each of R^8 to R^{10} is independently C_{1-10} alkyl, C_6-C_{10} aryl, C_6-C_{10} aralkyl, or C_6-C_{10} aryloxyalkyl. Preferred examples of R^8 are methyl, isopropyl, phenyl, benzyl, and phenoxyethyl. Preferred examples of R^9 and R^{10} are C_{1-4} alkyl group.

[0141] A preferred embodiment of the second aspect is that the nucleoside 3'-phosphoramidite derivative is represented by formula (Va') or (Vb').

[0142]



[0143] In the formula (Va') and (Vb'), G^1 , G^2 , G^5 , Bs, R^2 , and R^3 are same as above. The nucleoside 3'-phosphoramidite derivative is a chiral monomer which is used to produce stereocontrolled phosphorus atom-modified nucleotides and oligonucleotide derivatives.


[0144] Preferred examples of the nucleoside 3'-phosphoramidite derivatives are represented by the formula 1a, 1b, 2a, 2b, 3a, 3b, 4a, 4b, 5a, 5b, 6a, 6b, 7a, 7b, 8a, 8b, 9a, 9b, 10a, 10b, 11a, 11b, 12a, 12b, 13a, 13b, 14a, 14b, 15a, 15b, 16a, 16b, 17a, 17b, 18a, 18b, 19a, 19b, 20a, 20b, 21a, 21b, 22a, 22b, 23a, 23b, or 24a. These formulas are described

at the Experimental section.

[0145] DMTr represents a 4,4'-dimethoxytrityl group and TOM represents a triisopropyl-siloxymethyl group.

[0146] The examples of using the nucleoside 3'-phosphoramidite derivative are disclosed in, e.g., JP 2005-89441 A. By repeating steps of condensation and de-protection, it is possible to lengthen the chain of oligonucleotide derivatives as disclosed therein.

[0147] Formula of such an oligonucleotide derivative is shown in formula (X).




[0149] In the formula (X), X represents sulfide (=S), C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ alkylthio, C₆-C₁₀ aryl, C₆-C₁₀ aralkyl, or C₆-C₁₀ aryloxyalkyl. Preferably, X represents sulfide (=S). "n" is an integer that represents 1 to 150, 1 to 100, 1 to 50, or 1 to 30. "n" may be preferably 2 to 100, preferably 10 to 100, preferably 10 to 50, and more preferably 15 to 30.

[0150] The third aspect of the invention relates to a method for synthesis of a stereo-controlled phosphorus atom-modified oligonucleotide derivative. First step is a step of reacting a molecule comprising an achiral H-phosphonate moiety, the first activating reagent and a chiral reagent or a salt thereof to form a monomer. The chiral reagent has chemical formula (I) or (I') and the monomer may be represented by formula (Va), (Vb), (Va'), or (Vb'). The monomer reacts with the second activating reagent and a nucleoside to form a condensed intermediate. Next step is a step of converting the condensed intermediate to the nucleic acid comprising a chiral X-phosphonate moiety. The method basically based on disclosure of WO 2010/064146 pamphlet. Namely, fundamental steps are disclosed as route A and route B therein. In the method the chiral reagent of the present invention is used.

[0151] First Scheme relates to synthesis of Chiral Oligos.

[0152]



[0153] Activation Step

An achiral H-phosphonate moiety is treated with the first activating reagent to form the first intermediate. In one embodiment, the first activating reagent is added to the reaction mixture during the condensation step. Use of the first activating reagent is dependent on reaction conditions such as solvents that are used for the reaction. Examples of the first activating reagent are phosgene, trichloromethyl chloroformate, bis(trichloromethyl)carbonate (BTC), oxalyl chloride, Ph_3PCl_2 , $(\text{PhO})_3\text{PCl}_2$, N,N'-bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BopCl), 1,3-dimethyl-2-(3-nitro-1,2,4-triazol-1-yl)-2-pyrrolidin-1-yl-1,3,2-diazaphospholidinium hexafluorophosphate (MNTP), or 3-nitro-1,2,4-triazol-1-yl-tris(pyrrolidin-1-yl)phosphonium hexafluorophosphate (PyNTP).

[0154] The example of achiral H-phosphonate moiety is a compound shown in the above Scheme. DBU represents 1,8-diazabicyclo[5.4.0]undec-7-ene. H⁺DBU may be, for example, ammonium ion, alkylammonium ion, heteroaromatic iminium ion, or heterocyclic iminium ion, any of which is primary, secondary, tertiary or quaternary, or a monovalent metal ion.

[0155] Reacting with Chiral Reagent

After the first activation step, the activated achiral H-phosphonate moiety reacts with a chiral reagent, which is represented by formula (I) or (I'), to form a chiral intermediate of formula (Va), (Vb), (Va'), or (Vb').

[0156] Stereospecific Condensation Step

A chiral intermediate of Formula Va ((Vb), (Va'), or (Vb')) is treated with the second activating reagent and a nucleoside to form a condensed intermediate. The nucleoside may be solidified. Examples of the second activating reagent are 4,5-dicyanoimidazole (DCI), 4,5-dichloroimidazole, 1-phenylimidazolium triflate (PhIMT), benzimidazolium triflate (BIT), benzotriazole, 3-nitro-1,2,4-triazole (NT), tetrazole,

5-ethylthiotetrazole (ETT), 5-benzylthiotetrazole (BTT), 5-(4-nitrophenyl)tetrazole, N-cyanomethylpyrrolidinium triflate (CMPT), N-cyanomethylpiperidinium triflate, N-cyanomethyldimethylammonium triflate. A chiral intermediate of Formula Va ((Vb), (Va'), or (Vb')) may be isolated as a monomer. Usually, the chiral intermediate of Va ((Vb), (Va'), or (Vb')) is not isolated and undergoes a reaction in the same pot with a nucleoside or modified nucleoside to provide a chiral phosphite compound, a condensed intermediate. In other embodiments, when the method is performed via solid phase synthesis, the solid support comprising the compound is filtered away from side products, impurities, and/or reagents.

[0157] Capping Step

If the final nucleic acid is larger than a dimer, the unreacted -OH moiety is capped with a blocking group and the chiral auxiliary in the compound may also be capped with a blocking group to form a capped condensed intermediate. If the final nucleic acid is a dimer, then the capping step is not necessary.

[0158] Modifying Step

The compound is modified by reaction with an electrophile. The capped condensed intermediate may be executed modifying step. In some embodiments of the method, the modifying step is performed using a sulfur electrophile, a selenium electrophile or a boronating agent. The preferred examples of modifying steps are step of oxidation and sulfurization.

[0159] In some embodiments of the method, the sulfur electrophile is a compound having one of the following formulas:

S_8 (Formula B), $Z^1-S-S-Z^2$, or $Z^1-S-V-Z^2$.


[0160] Z^1 and Z^2 are

independently alkyl, aminoalkyl, cycloalkyl, heterocyclic, cycloalkylalkyl, heterocycloalkyl,

aryl, heteroaryl, alkyloxy, aryloxy, heteroaryloxy, acyl, amide, imide, or thiocarbonyl, or Z^1

and Z^2 are taken together to form a 3 to 8 membered alicyclic or heterocyclic ring, which may be substituted or unsubstituted; V is SO_2 , O, or NR^f ; and R^f is hydrogen, alkyl, alkenyl, alkynyl, or aryl.

[0161] In some embodiments of the method, the sulfur electrophile is a compound of following Formula A, B, C, D, E, or F:




[0162] In some embodiments of the method, the selenium electrophile is a compound having

one of the following formulas:

[0163] Se (Formula G), Z^3 -Se-Se- Z^4 , or Z^3 -Se-V- Z^4

[0164] Z^3 and Z^4 are independently alkyl, aminoalkyl, cycloalkyl, heterocyclic, cycloalkylalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxy, aryloxy, heteroaryloxy, acyl, amide, imide, or thiocarbonyl, or Z^3 and Z^4 are taken together to form a 3 to 8 membered alicyclic or heterocyclic ring, which may be substituted or unsubstituted; V is SO_2 , S, O, or NR^f ; and R^f is hydrogen, alkyl, alkenyl, alkynyl, or aryl.

[0165] In some embodiments of the method, the selenium electrophile is a compound of Formula G, H, I, J, K, or L.



[0166] In some embodiments of the method, the boronating agent is borane-N,N-diisopropylethylamine (BH_3 DIPEA), borane-pyridine (BH_3 Py), borane-2-chloropyridine (BH_3 CPy), borane-aniline (BH_3 An), borane-tetrahydrofuran (BH_3 THF), or borane-dimethylsulfide (BH_3 Me_2S).

[0167] In some embodiments of the method, the modifying step is oxidation step. Oxidation step is disclosed in, e.g., JP 2010-265304 A and WO2010/064146.

[0168] Chain Elongation Cycle and De-protection Step

The capped condensed intermediate is deblocked to remove the blocking group at the 5'-end of the growing nucleic acid chain to provide a compound. The compound is optionally allowed to re-enter the chain elongation cycle to form a condensed intermediate, a capped condensed intermediate, a modified capped condensed intermediate, and a 5'-deprotected modified capped intermediate. Following at least one round of chain elongation cycle, the 5'-deprotected modified capped intermediate is further deblocked by removal of the chiral auxiliary ligand and other protecting groups, e.g., nucleobase, modified nucleobase, sugar and modified sugar protecting groups, to provide a nucleic acid. In other embodiments, the nucleoside comprising a 5'-OH moiety is an intermediate from a previous chain elongation cycle as described herein. In yet other embodiments, the nucleoside comprising a 5'-OH moiety is an intermediate obtained from another known nucleic acid synthetic method. In embodiments where a solid support is used, the phosphorus-atom modified nucleic acid is then cleaved from the solid support. In certain embodiments, the nucleic acid is left attached on the solid support for purification purposes and then cleaved from the solid support following purification.


[0169] Based on the present method, it is possible to use stable and commercially available materials as starting materials. It is possible to produce stereocontrolled phosphorus

atom-modified oligonucleotide derivatives using an achiral starting material.

[0170] As shown in a working example, the method of the present invention does not cause degradations under the de-protection steps. Further the method does not require special capping agents to produce phosphorus atom-modified oligonucleotide derivatives.

[0171] The fourth aspect of the invention relates to a method for the synthesis of stereo-controlled phosphorus atom-modified oligonucleotide derivatives using a chiral monomer. The first step is reacting a nucleoside 3'-phosphoramidite derivative which is represented by formula (Va), (Vb), (Va'), or (Vb') with the second activating reagent and a nucleoside to form a condensed intermediate. The second step is converting the condensed intermediate to the nucleic acid comprising a chiral X-phosphonate moiety.


[0172] Second Scheme relates to synthesis of Chiral Oligos using a monomer of Formula Va ((Vb), (Va'), or (Vb')). The second Scheme based on the method disclosed in JP 2005-89441 A.



[0174] The detailed conditions of the above scheme are similar to that of the first scheme. The starting material of formula Va (Vb), especially of formula Va' (or Vb'), is chemically stable. As shown in a working example, the method of the present invention does not cause degradations under the de-protection steps. Further the method does not require special capping agents to produce phosphorus atom-modified oligonucleotide derivatives.

[0175] Mechanism for the removal of auxiliaries is shown as follows:

[0176]



[0177] In the above scheme, Nu stands for Nucleophile. The above mechanism is thought to be different from the previous mechanism for the removal of auxiliaries.

Examples

[0178] Abbreviation

ac: acetyl

bz: benzoyl

CSO: (1S)-(+)-(10-camphorsulfonyl)oxaziridine

DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene

DCA: dichloroacetic acid

DCM: dichloromethane, CH₂Cl₂

DMTr: 4,4'-dimethoxytrityl

Tr: trityl, triphenylmethyl

MeIm: N-methylimidazole

NIS: N-iodosuccinimide

pac: phenoxyacetyl

Ph: phenyl

PhIMT: N-phenylimidazolium triflate

POS: 3-phenyl-1,2,4-dithiazoline-5-one

TBS: tert-butyldimethylsilyl

TBDPS: tert-butyldiphenylsilyl


TOM: triisopropylsiloxymethyl

TFA: trifluoroacetic acid

Example 1

[0179]

(S)-1-Tritylpyrrolidin-2-carbaldehyde (I-a).



I-a


Compound I-a was synthesized from L-proline according to the procedure described

in the literature (Guga, P. Curr. Top. Med. Chem. 2007, 7, 695-713.).

Example 2

[0180]

(*R*)-1-Tritylpyrrolidin-2-carbaldehyde (I-b).




Compound I-b was synthesized from D-proline in a similar manner to compound I-a.

Example 3

[0181]

(*S*)-2-(Methyldiphenylsilyl)-1-((*S*)-1-tritylpyrrolidin-2-yl)ethanol (II-a).




To a solution of methyldiphenylsilylmethyl magnesium chloride in THF prepared from chloromethyldiphenylmethylsilane (4.02 g, 16.3 mmol) and magnesium (402 mg, 16.3 mmol) in THF (14 mL) was added I-a (2.79 g, 8.14 mmol) in THF (30 mL) solution with ice cooling. After stirring for 1.5 h with ice cooling, the mixture warmed to room temperature and continued stirring for 30 min. Saturated aqueous NH₄Cl (100 mL) was added to the reaction mixture at 0 degrees C, and extraction was performed with diethylether (100 mL) for three times. The combined extract was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was chromatographed on silica gel afforded II-a as a colorless foam (3.91 g, 87%).

¹H NMR (300 MHz, CDCl₃) δ 7.48-7.08 (25H, m), 4.33-4.23 (1H, m), 3.16-2.89 (3H, m), 2.84 (1H, brs), 1.70-1.54 (1H, m), 1.35 (1H, dd, J = 14.7, 6.3Hz), 1.10 (1H, dd, J = 14.7, 8.1Hz), 1.18-1.05 (1H, m), 1.04-0.90 (1H, m), 0.34 (3H, s), -0.17- -0.36 (1H, m).

Example 4

[0182]

(*S*)-2-(Methyldiphenylsilyl)-1-((*S*)-pyrrolidin-2-yl)ethanol (III-a).



II-a (3.91 g, 7.06 mmol) was dissolved in 3% DCA in DCM (70 mL), and stirred for 10 min at room temperature. To the mixture, 1M NaOH (200 mL) was added, and extraction was performed with DCM (100 mL) for three times. The combined extract was


dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was chromatographed on silica gel afforded III-a as a light yellow oil (1.99 g, 90%).

¹H NMR (300 MHz, CDCl₃) δ 7.57-7.52 (5H, m), 7.38-7.33 (5H, m), 3.77 (1H, ddd, J = 8.9, 5.4, 3.5 Hz), 3.01 (1H, dt, J = 7.4, 3.6 Hz), 2.97-2.79 (2H, m), 2.27 (2H, brs), 1.76-1.53 (4H, m), 1.38 (1H, dd, J = 15.0, 9.0 Hz), 1.24 (1H, dd, J = 15.0, 5.4 Hz), 0.65 (3H, s); ¹³C NMR (100.4 MHz, CDCl₃) δ 137.4, 137.1, 134.6, 134.5, 129.1, 127.8, 69.5, 64.1, 47.0, 25.8, 24.0, 19.6, -3.4. MALDI TOF-MS m/z Calcd for C₁₉H₂₆NOSi [M+H]⁺ 312.18, found 312.06.

Example 5

[0183]

(R)-2-(Methyldiphenylsilyl)-1-((R)-1-tritylpyrrolidin-2-yl)ethanol (II-b).




Compound II-b was obtained by using I-b instead of I-a in a similar manner to compound II-a.

¹H NMR (300 MHz, CDCl₃) δ 7.48-7.12 (25H, m), 4.33-4.24 (1H, m), 3.16-2.89 (3H, m), 2.86 (1H, brs), 1.69-1.52 (1H, m), 1.35 (1H, dd, J = 14.4, 6.0 Hz), 1.10 (1H, dd, J = 14.4, 8.4 Hz), 1.18-1.05 (1H, m), 1.03-0.89 (1H, m), 0.33 (3H, s), -0.19- -0.39 (1H, m); ¹³C NMR (75.5 MHz, CDCl₃) δ 144.5, 137.5, 136.8, 134.6, 134.3, 129.8, 129.0, 127.8, 127.7, 127.4, 126.1, 77.9, 71.7, 65.1, 53.5, 25.0, 24.8, 19.6, -4.0. MALDI TOF-MS m/z Calcd for C₃₈H₄₀NOSi [M+H]⁺ 554.29, found 554.09.

Example 6

[0184]

(R)-2-(Methyldiphenylsilyl)-1-((R)-1-pyrrolidin-2-yl)ethanol (III-b).




Compound III-b was obtained by using II-b instead of II-a in a similar manner to compound III-a.

¹H NMR (300 MHz, CDCl₃) δ 7.58-7.52 (5H, m), 7.38-7.33 (5H, m), 3.78 (1H, ddd, J = 9.0, 5.1, 3.6 Hz), 3.00 (1H, dt, J = 7.4, 3.3 Hz), 2.97-2.78 (2H, m), 2.19 (2H, brs), 1.76-1.53 (4H, m), 1.38 (1H, dd, J = 14.6, 9.0 Hz), 1.24 (1H, dd, J = 14.6, 5.1 Hz), 0.66 (3H, s); ¹³C NMR (75.5 MHz, CDCl₃) δ 137.5, 137.1, 134.5, 134.4, 129.0, 127.7, 69.2, 64.2, 46.9, 25.8, 24.0, 19.7, -3.4. MALDI TOF-MS m/z Calcd for C₁₉H₂₆NOSi [M+H]⁺ 312.18, found 312.09.

Example 7

[0185] **(S)-2-(Trimethylsilyl)-1-((S)-1-tritylpyrrolidin-2-yl)ethanol (IV-a).**




Compound IV-a was obtained by using "chloromethyltrimethylsilane" instead of "chloromethyldiphenylmethyilsilane" in a similar manner to compound II-a.

¹H NMR (300 MHz, CDCl₃) δ 7.58-7.51 (5H, m), 7.31-7.14 (10H, m), 4.13 (1H, dt, J = 7.5, 3.0Hz), 3.39-3.31 (1H, m), 3.20-2.99 (2H, m), 2.84 (1H, s), 1.74-1.57 (1H, m), 1.29-1.10 (2H, m), 0.74 (1H, dd, J = 14.4, 7.2Hz), 0.46 (1H, dd, J = 14.4, 7.2Hz), -0.15 (9H, s). MALDI TOF-MS m/z Calcd for C₂₈H₃₆NOSi [M+H]⁺ 430.26, found 430.09.

Example 8

[0186] **(S)-2-(Trimethylsilyl)-1-((S)-1-pyrrolidin-2-yl)ethanol (V-a).**




Compound V-a was obtained by using IV-a instead of II-a in a similar manner to compound III-a.

¹H NMR (300 MHz, CDCl₃) δ 3.76 (1H, ddd, J = 8.8, 5.7, 3.3Hz), 3.08 (1H, dt, J = 7.8, 3.3Hz), 3.02-2.87 (2H, m), 2.48 (2H, brs), 1.81-1.58 (4H, m), 0.83 (1H, dd, J = 14.7, 8.7Hz), 0.68 (1H, dd, J = 14.7, 6.0Hz), 0.05 (9H, s); ¹³C NMR (75.5 MHz, CDCl₃) δ 69.6, 64.3, 46.9, 25.8, 23.9, 22.0, -0.8. MALDI TOF-MS m/z Calcd for C₉H₂₂NOSi [M+H]⁺ 188.15, found 188.00.

Example 9

[0187] **(R)-2,2-Diphenyl-1-((S)-1-tritylpyrrolidin-2-yl)ethanol (VI-a).**



To a solution of diphenylmethane (6.7 mL, 40mmol) in anhydrous THF (36 mL), n-BuLi (1.67M solution of Hexane, 24mL, 40mmol) was added dropwise at room temperature and stirred for 1 h. To the mixture, I-a (3.41g, 10mmol), which was dried by


repeated coevaporations with toluene, in anhydrous THF (40mL) was slowly added at 0 degrees C, and continued stirring for 45 min. A saturated NH₄Cl aqueous solution (100mL) and Et₂O (100mL) were then added, and the organic layer was separated and the aqueous layer was extracted with Et₂O (2 x 100mL). The organic layer were combined, dried over Na₂SO₄, filterd and concentrated under reduced pressure. The residue was purified by chromatography on silica gel to afford VI-a (1.41g, 28%) as white foam.

¹H NMR (300 MHz, CDCl₃) d 7.45-7.01 (23H, m), 6.67-6.61 (2H, m), 4.80 (1H, d, J = 10.8Hz), 3.63 (1H, d, J = 10.8Hz), 3.36-3.27 (1H, m), 3.23-3.09 (1H, m), 3.02-2.89 (1H, m), 2.66 (1H, s), 1.90-1.75 (1H, m), 1.32-1.04 (2H, m), 0- -0.18 (1H, m).

Example 10

[0188]

(*R*)-2,2-Diphenyl-1-((*S*)-pyrrolidin-2-yl)ethanol (VII-a).




Compound VII-a was obtained by using VI-a instead of II-a in a similar manner to compound III-a.

¹H NMR (300 MHz, CDCl₃) d 7.44-7.38 (2H, m), 7.33-7.14 (8H, m), 4.46 (1H, dd, J = 9.9, 3.3Hz), 3.91 (1H, d, J = 9.9Hz), 3.02-2.88 (2H, m), 2.81-2.69 (1H, m), 2.52 (2H, brs), 1.88-1.56 (4H, m); ¹³C NMR (75.5 MHz, CDCl₃) d 142.3, 142.0, 128.6, 128.5, 128.4, 128.2, 126.5, 126.4, 73.5, 60.1, 55.8, 46.6, 25.8, 23.4. MALDI TOF-MS m/z Calcd for C₁₈H₂₂NO [M+H]⁺ 268.17, found 268.06.

Example 11

[0189]

(*S*)-2,2-Diphenyl-1-((*R*)-1-tritylpyrrolidin-2-yl)ethanol (VI-b).



Compound VI-b was obtained by using I-b instead of I-a in a similar manner to compound VI-a.

¹H NMR (300 MHz, CDCl₃) d 7.44-7.37 (6H, m), 7.30-7.01 (17H, m), 6.66-6.61 (2H, m), 4.80 (1H, d, J = 10.8Hz), 3.63 (1H, d, J = 10.8Hz), 3.36-3.28 (1H, m), 3.22-3.09 (1H, m), 3.01-2.89 (1H, m), 2.66 (1H, s), 1.90-1.75 (1H, m), 1.29-1.04 (2H, m), 0.00--0.19 (1H, m); ¹³C NMR (75.5 MHz, CDCl₃) d 144.2, 142.9, 141.6, 130.0, 128.5,


128.4, 127.9, 127.8, 127.4, 126.4, 126.2, 77.9, 75.9, 61.9, 55.4, 53.4, 24.7, 24.5.

MALDI TOF-MS m/z Calcd for $C_{37}H_{36}NO$ $[M+H]^+$ 510.28, found 510.11.

Example 12

[0190]

(*S*)-2,2-Diphenyl-1-((*R*)-pyrrolidin-2-yl)ethanol (VII-b).




Compound VII-b was obtained by using VI-b instead of VI-a in a similar manner to compound VII-a.

1H NMR (300 MHz, $CDCl_3$) δ 7.45-7.14 (10H, m), 4.45 (1H, dd, $J = 9.9, 3.3$ Hz), 3.91 (1H, d, $J = 9.9$ Hz), 3.00-2.89 (2H, m), 2.82-2.71 (1H, m), 2.40 (2H, brs), 1.87-1.55 (4H, m); ^{13}C NMR (75.5 MHz, $CDCl_3$) δ 142.3, 142.0, 128.5, 128.3, 128.1, 126.3, 126.2, 73.4, 60.1, 55.9, 46.5, 25.8, 23.5. MALDI TOF-MS m/z Calcd for $C_{18}H_{22}NO$ $[M+H]^+$ 268.17, found 268.03.

Example 13

[0191]

(*R*)-2-(4-Nitrophenyl)-1-((*S*)-1-tritylpyrrolidin-2-yl)ethanol (VIII-a).




Compound VIII-a was obtained by using "4-nitrobenzylchloride" instead of "diphenylmethane" in a similar manner to compound VI-a.

1H NMR (300 MHz, $CDCl_3$) δ 8.09-8.03 (2H, m), 7.49-7.43 (6H, m), 7.28-7.09 (11H, m), 4.23 (1H, ddd, $J = 8.3, 5.6, 3.0$ Hz), 3.43-3.33 (1H, m), 3.23-3.11 (1H, m), 3.07-2.96 (1H, m), 2.83 (1H, brs), 2.74 (1H, dd, $J = 13.8, 8.4$ Hz), 2.49 (1H, dd, $J = 13.8, 5.1$ Hz), 1.83-1.67 (1H, m), 1.41-1.17 (2H, m), 0.27-0.08 (1H, m); ^{13}C NMR (75.5 MHz, $CDCl_3$) δ 147.3, 146.3, 144.3, 129.8, 129.6, 127.5, 126.3, 123.4, 77.9, 74.8, 63.5, 53.2, 39.5, 25.0, 24.9. MALDI TOF-MS m/z Calcd for $C_{31}H_{31}N_2O_3$ $[M+H]^+$ 479.23, found 479.08.

Example 14

[0192]


(*R*)-2-(4-Nitrophenyl)-1-((*S*)-pyrrolidin-2-yl)ethanol (IX-a).**IX-a**

Compound IX-a was obtained by using VIII-a instead of VI-a in a similar manner to compound VII-a.

¹H NMR (300 MHz, CDCl₃) δ 8.15 (2H, d, J = 8.7Hz), 7.42 (2H, d, J = 8.7Hz), 3.86-3.79 (1H, m), 3.16-3.07 (1H, m), 2.99-2.68 (6H, m), 1.84-1.68 (4H, m); ¹³C NMR (75.5 MHz, CDCl₃) δ 147.4, 146.2, 129.9, 123.2, 72.4, 62.0, 46.6, 40.4, 25.7, 24.4. MALDI TOF-MS m/z Calcd for C₁₂H₁₇N₂O₃ [M+H]⁺ 237.12, found 237.01.

Example 15

[0193] **(*S*)-2-(4-Nitrophenyl)-1-((*R*)-1-tritylpyrrolidin-2-yl)ethanol (VIII-b).**


**VIII-b**

Compound VIII-b was obtained by using I-b instead of I-a in a similar manner to compound VIII-a.

¹H NMR (300 MHz, CDCl₃) δ 8.09-8.04 (2H, m), 7.49-7.43 (6H, m), 7.28-7.09 (11H, m), 4.22 (1H, ddd, J = 8.4, 5.6, 3.0Hz), 3.43-3.33 (1H, m), 3.24-3.10 (1H, m), 3.08-2.94 (1H, m), 2.81 (1H, brs), 2.75 (1H, dd, J = 14.0, 8.1Hz), 2.49 (1H, dd, J = 14.0, 5.1Hz), 1.81-1.67 (1H, m), 1.40-1.16 (2H, m), 0.26-0.09 (1H, m); ¹³C NMR (75.5 MHz, CDCl₃) δ 147.3, 144.3, 129.8, 129.6, 129.4, 126.3, 123.5, 77.9, 74.8, 63.5, 53.2, 39.5, 25.0, 24.9. MALDI TOF-MS m/z Calcd for C₃₁H₃₁N₂O₃ [M+H]⁺ 479.23, found 479.08.

Example 16

[0194] **(*S*)-2-(4-Nitrophenyl)-1-((*R*)-pyrrolidin-2-yl)ethanol (IX-b).**

**IX-b**


Compound IX-b was obtained by using VIII-b instead of VIII-a in a similar manner to compound IX-a.

^1H NMR (300 MHz, CDCl_3) δ 8.19-8.13 (2H, m), 7.45-7.39 (2H, m), 3.83 (1H, ddd, $J = 7.7, 5.4, 3.9\text{Hz}$), 3.14 (1H, dt, $J = 7.7, 3.9\text{Hz}$), 3.01-2.87 (2H, m), 2.83 (1H, d, $J = 3.3\text{Hz}$), 2.81 (1H, s), 2.62 (2H, brs), 1.79-1.72 (4H, m); ^{13}C NMR (75.5 MHz, CDCl_3) δ 147.3, 146.5, 130.0, 123.5, 72.7, 61.7, 46.7, 40.1, 25.8, 24.2. MALDI TOF-MS m/z Calcd for $\text{C}_{12}\text{H}_{17}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$ 237.12, found 237.02.

Example 17

[0195]

(*R*)-(9*H*-Fluorene-9-yl)((*S*)-1-tritylpyrrolidin-2-yl)methanol (X-a).



X-a


Compound X-a was obtained by using "fluorene" instead of "diphenylmethane" in a similar manner to compound VI-a.

^1H NMR (300 MHz, CDCl_3) δ 7.70 (1H, d, $J = 7.5\text{Hz}$), 7.66 (1H, d, $J = 7.8\text{Hz}$), 7.55 (2H, d, $J = 7.5\text{Hz}$), 7.44-7.09 (18H, m), 6.87-6.62 (1H, m), 4.55-4.48 (1H, m), 4.06 (1H, d, $J = 7.5\text{Hz}$), 3.43-3.34 (1H, m), 3.18-3.06 (1H, m), 2.98-2.88 (1H, m), 2.85 (1H, brs), 1.42-1.24 (1H, m), 1.18-1.04 (1H, m), 0.53-0.39 (1H, m), -0.02- -0.20 (1H, m); MALDI TOF-MS m/z Calcd for $\text{C}_{37}\text{H}_{34}\text{NO}$ $[\text{M}+\text{H}]^+$ 508.26, found 508.12.

Example 18

[0196]

(*R*)-(9*H*-Fluorene-9-yl)((*S*)-pyrrolidin-2-yl)methanol (XI-a).




XI-a

Compound XI-a was obtained by using X-a instead of II-a in a similar manner to compound III-a.

^1H NMR (300 MHz, CDCl_3) δ 7.76 (2H, d, $J = 7.5\text{Hz}$), 7.68 (2H, t, $J = 8.0\text{Hz}$), 7.43-7.35 (2H, m), 7.34-7.25 (2H, m), 4.28 (1H, d, $J = 6.3\text{Hz}$), 4.03 (1H, dd, $J = 6.5, 4.2\text{Hz}$), 3.19-3.11 (1H, m), 2.97-2.88 (1H, m), 2.86-2.76 (1H, m), 2.02 (2H, brs), 1.77-1.53 (3H, m), 1.38-1.23 (1H, m); MALDI TOF-MS m/z Calcd for $\text{C}_{18}\text{H}_{20}\text{NO}$ $[\text{M}+\text{H}]^+$ 266.15, found 266.04.

Example 19

[0197]


(S)-2-Tosyl-1-((S)-1-tritylpyrrolidin-2-yl)ethanol (XII-a).

Compound XII-a was obtained by using "chloromethyl p-tolyl sulfone" instead of "chloromethyldiphenylmethyilsilane" in a similar manner to compound II-a.

¹H NMR (600 MHz, CDCl₃) δ 7.66 (2H, d, J = 8.4Hz), 7.48-7.44 (6H, m), 7.35 (2H, d, J = 7.2Hz), 7.21-7.13 (9H, m), 4.39-4.36 (1H, m), 3.33 (1H, s), 3.24-3.20 (1H, m), 3.19-3.10 (2H, m), 2.98-2.92 (2H, m), 2.49 (3H, s), 1.55-1.49 (1H, m), 1.33-1.26 (1H, m), 1.12-1.04 (1H, m), 0.22-0.14 (1H, m); ¹³C NMR (150.9 MHz, CDCl₃) δ 144.6, 144.5, 136.3, 129.9, 129.5, 128.1, 127.5, 126.2, 78.0, 69.1, 63.9, 60.2, 52.6, 25.5, 24.7, 21.7.

Example 20

[0198]


(S)-2-Tosyl-1-((S)-1-tritylpyrrolidin-2-yl)ethanol (XIII-a).

Compound XIII-a was obtained by using XII-a instead of II-a in a similar manner to compound III-a.

¹H NMR (600 MHz, CDCl₃) δ 7.82 (2H, d, J = 8.4Hz), 7.37 (2H, d, J = 8.4Hz), 4.01 (1H, ddd, J = 12.0, 5.1, 3.0Hz), 3.32 (1H, dd, J = 14.4, 3.0Hz), 3.25 (1H, dd, J = 14.4, 9.0Hz), 3.16 (1H, dt, J = 7.8, 5.1Hz), 2.90-2.82 (2H, m), 2.46 (3H, s), 2.04 (2H, brs), 1.78-1.63 (3H, m), 1.62-1.55 (1H, m); ¹³C NMR (150.9 MHz, CDCl₃) δ 144.5, 136.7, 129.7, 127.7, 67.4, 61.8, 60.1, 46.7, 25.7, 21.4. MALDI TOF-MS m/z Calcd for C₁₃H₂₀NO₃S [M+H]⁺ 270.12, found 270.04.

Example 2

[0199]

(R)-2-Tosyl-1-((R)-1-tritylpyrrolidin-2-yl)ethanol (XII-b).


Compound XII-b was obtained by using I-b instead of I-a in a similar manner to compound XII-a.

¹H NMR (600 MHz, CDCl₃) δ 7.66 (2H, d, J = 8.4Hz), 7.47-7.44 (6H, m), 7.35 (2H, d, J = 7.8Hz), 7.21-7.13 (9H, m), 4.37 (1H, dt, J = 8.6, 2.4Hz), 3.33 (1H, s), 3.23-3.20 (1H, m), 3.19-3.12 (2H, m), 2.98-2.92 (2H, m), 2.49 (3H, s), 1.56-1.49 (1H, m), 1.32-1.26 (1H, m), 1.11-1.03 (1H, m), 0.23-0.15 (1H, m); ¹³C NMR (150.9 MHz, CDCl₃) δ 144.6, 144.5, 136.3, 129.9, 129.6, 128.1, 127.6, 126.2, 78.0, 69.1, 63.9, 60.2, 52.6, 25.5, 24.7, 21.7.

Example 21

[0200]

(*R*)-2-Tosyl-1-((*R*)-1-tritylpyrrolidin-2-yl)ethanol (XIII-b).



XIII-b


Compound XIII-b was obtained by using XII-b instead of XII-a in a similar manner to compound XIII-a.

¹H NMR (600 MHz, CDCl₃) δ 7.82 (2H, d, J = 8.4Hz), 7.37 (2H, d, J = 8.4Hz), 4.01 (1H, ddd, J = 9.0, 5.1, 3.0Hz), 3.32 (1H, dd, J = 14.4, 3.0Hz), 3.25 (1H, dd, J = 14.4, 9.0Hz), 3.17 (1H, dt, J = 7.2, 5.1Hz), 2.89-2.83 (2H, m), 2.46 (3H, s), 2.04 (2H, brs), 1.79-1.64 (3H, m), 1.62-1.55 (1H, m); ¹³C NMR (150.9 MHz, CDCl₃) δ 144.8, 136.6, 129.8, 127.9, 67.7, 61.8, 60.1, 46.8, 25.9, 25.8, 21.6. MALDI TOF-MS m/z Calcd for C₁₃H₂₀NO₃S [M+H]⁺ 270.12, found 270.05.

Example 22

[0201]

Oxazaphospholidine monomer 3a.



3a

III-a (560 mg, 1.80 mmol) were dried by repeated coevaporations with dry toluene


and dissolved in dry diethylether (0.90 mL) under argon. N-Methylmorpholine (400 mL, 3.60 mmol) was added to the solution, and the resultant solution was added dropwise to a solution of PCl_3 (160 mL, 1.80 mmol) in dry diethylether (0.90 mL) at 0 degrees C under argon with stirring. The mixture was then allowed to warm to room temperature and stirred for 30 min. The resultant N-methylmorpholine hydrochloride was removed by filtration under nitrogen, and the filtrate was concentrated to dryness under reduced pressure to afford crude 2-chloro-1,3,2-oxazaphospholidine derivative. The crude materials were dissolved in freshly distilled THF (3.6 mL) to make 0.5 M solutions, which were used to synthesize the nucleoside 3'-O-oxazaphospholidines without further purification.

5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine (636 mg, 0.84 mmol) was dried by repeated coevaporations with dry toluene, and dissolved in freshly distilled THF (2.5 mL) under argon. Et_3N (0.58 mL, 4.2 mmol) was added, and the mixture was cooled to -78 degrees C. A 0.5 M solution of the corresponding crude 2-chloro-1,3,2-oxazaphospholidine derivative in freshly distilled THF (3.6 mL, 1.80 mmol) was added dropwise via a syringe, and the mixture was stirred for 15 min at room temperature. A saturated NaHCO_3 aqueous solution (70 mL) and CHCl_3 (70 mL) were then added, and the organic layer was separated and washed with saturated NaHCO_3 aqueous solutions (2 x 70 mL). The combined aqueous layers were back-extracted with CHCl_3 (70 mL). The organic layers were combined, dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel to afford 3a (829 mg, 90%) as a white foam.

^1H NMR (300 MHz, CDCl_3) δ 8.77 (1H, brs), 7.99 (1H, s), 7.54-6.98 (24H, m), 6.81-6.73 (4H, m), 6.35 (1H, dd, $J = 8.0, 6.3\text{Hz}$), 4.89-4.73 (4H, m), 4.68 (2H, brs), 4.05-3.98 (1H, m), 3.75 (6H, s), 3.62-3.46 (1H, m), 3.41-3.20 (3H, m), 3.18-3.04 (1H, m), 3.08 (2H, t, $J = 6.6\text{Hz}$), 2.58-2.36 (2H, m), 1.94-1.59 (2H, m), 1.56 (1H, dd, $J = 15.0, 8.7\text{Hz}$), 1.43 (1H, dd, $J = 15.0, 5.7\text{Hz}$), 1.33-1.16 (2H, m), 0.62 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 153.5 (1P, s).

Example 23

[0202]


Oxazaphospholidine monomer 3b.**3b**

Compound 3b was obtained by using III-b instead of III-a in a similar manner to compound 3a.

^1H NMR (300 MHz, CDCl_3) δ 8.80 (1H, brs), 7.96 (1H, s), 7.54-6.96 (24H, m), 6.79-6.71 (4H, m), 6.19 (1H, t, $J = 6.6\text{Hz}$), 4.90-4.73 (4H, m), 4.66 (2H, brs), 4.16-4.08 (1H, m), 3.76 (6H, s), 3.60-3.36 (2H, m), 3.29 (1H, d, $J = 3.9\text{Hz}$), 3.27-3.12 (2H, m), 3.09 (2H, t, $J = 6.6\text{Hz}$), 2.59-2.46 (1H, m), 2.07-1.97 (1H, m), 1.94-1.41 (5H, m), 1.36-1.18 (1H, m), 0.65 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 157.1 (1P, s).

Example 24

[0203]

Oxazaphospholidine monomer 1a.**1a**


Compound 1a was obtained by using "5'-O-(DMTr)-6-N-(benzoyl)adenosine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

^1H NMR (600 MHz, CDCl_3) δ 8.71 (1H, s), 8.12 (1H, s), 8.04 (2H, d, $J = 7.8\text{Hz}$), 7.62-7.15 (23H, m), 6.80-6.75 (4H, m), 6.37 (1H, dd, $J = 7.8, 6.0\text{Hz}$), 4.94-4.88 (1H, m), 4.80 (1H, ddd, $J = 12.0, 6.0, 5.4\text{Hz}$), 4.07-4.04 (1H, m), 3.76 (6H, s), 3.58-3.49 (1H, m), 3.41-3.34 (1H, m), 3.33 (1H, dd, $J = 10.8, 4.8\text{Hz}$), 3.25 (1H, dd, $J = 10.8, 4.8\text{Hz}$), 3.13-3.06 (1H, m), 2.66-2.58 (1H, m), 2.40-2.35 (1H, m), 1.91-1.84 (1H, m), 1.73-1.66 (1H, m), 1.56 (1H, dd, $J = 15.0, 9.0\text{Hz}$), 1.44 (1H, dd, $J = 15.0, 5.4\text{Hz}$), 1.47-1.41 (1H, m), 1.30-1.23 (1H, m), 0.63 (3H, s); ^{31}P NMR (243.0 MHz, CDCl_3) δ 151.8 (1P, s).

Example 25

[0204]

Oxazaphospholidine monomer 1b.




Compound 1b was obtained by using III-b instead of III-a in a similar manner to compound 1a.

^1H NMR (300 MHz, CDCl_3) δ 9.06 (1H, brs), 8.76 (1H, s), 8.12 (1H, s), 8.07-7.99 (2H, m), 7.64-7.14 (22H, m), 6.83-6.75 (4H, m), 6.25 (1H, t, $J = 6.6\text{Hz}$), 4.86-4.75 (2H, m), 4.20-4.15 (1H, m), 3.77 (6H, s), 3.61-3.38 (2H, m), 3.36 (1H, dd, $J = 10.2, 4.2\text{Hz}$), 3.27 (1H, dd, $J = 10.2, 4.2\text{Hz}$), 3.27-3.13 (1H, m), 2.71-2.59 (1H, m), 2.12-2.01 (1H, m), 1.94-1.42 (5H, m), 1.36-1.20 (1H, m), 0.67 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 157.3 (1P, s).

Example 26

[0205]


Oxazaphospholidine monomer 2a.

Compound 2a was obtained by using "5'-O-(DMTr)-4-N-(isobutyryl)cytidine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

¹H NMR (300 MHz, CDCl₃) δ 8.33 (1H, brs), 8.17 (1H, d, J = 7.5Hz), 7.52-7.22 (19H, m), 7.07 (1H, d, J = 7.5Hz), 6.88-6.81 (4H, m), 6.20 (1H, t, J = 6.2Hz), 4.81-4.64 (2H, m), 3.93-3.87 (1H, m), 3.79 (6H, s), 3.59-3.43 (1H, m), 3.39-3.29 (3H, m), 3.16-3.02 (1H, m), 2.69-2.52 (2H, m), 2.12-2.00 (1H, m), 1.91-1.50 (3H, m), 1.47-1.32 (2H, m), 1.27-1.16 (7H, m), 0.60 (3H, s); ³¹P NMR (121.5 MHz, CDCl₃) δ 154.8 (1P, s).

Example 27

[0206]

Oxazaphospholidine monomer 2b.

Compound 2b was obtained by using III-b instead of III-a in a similar manner to


compound 2a.

^1H NMR (300 MHz, CDCl_3) δ 8.33 (1H, d, $J = 7.5\text{Hz}$), 8.23 (1H, brs), 7.57-7.22 (19H, m), 7.12 (1H, d, $J = 7.5\text{Hz}$), 6.88-6.81 (4H, m), 6.15 (1H, dd, $J = 6.6, 4.2\text{Hz}$), 4.82-4.63 (2H, m), 4.03-3.97 (1H, m), 3.80 (6H, s), 3.55-3.26 (4H, m), 3.19-3.05 (1H, m), 2.59 (1H, quintet, $J = 6.9\text{Hz}$), 2.39-2.27 (1H, m), 2.21-2.10 (1H, m), 1.90-1.56 (3H, m), 1.50-1.32 (2H, m), 1.26-1.17 (7H, m), 0.66 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 157.2 (1P, s).

Example 28

[0207]

Oxazaphospholidine monomer 4a.




Compound 4a was obtained by using "5'-O-(DMTr)thymidine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

^1H NMR (300 MHz, CDCl_3) δ 7.58-7.23 (21H, m), 6.86-6.79 (4H, m), 6.35 (1H, dd, $J = 8.1, 5.7\text{Hz}$), 4.79-4.67 (2H, m), 3.83-3.78 (1H, m), 3.78 (6H, s), 3.59-3.43 (1H, m), 3.34 (1H, dd, $J = 10.5, 2.4\text{Hz}$), 3.35-3.24 (1H, m), 3.20 (1H, dd, $J = 10.5, 2.4\text{Hz}$), 3.16-3.02 (1H, m), 2.36-2.26 (1H, m), 2.15-2.02 (1H, m), 1.92-1.77 (1H, m), 1.74-1.59 (1H, m), 1.52 (1H, dd, $J = 14.7, 9.0\text{Hz}$), 1.40 (3H, s), 1.45-1.15 (3H, m), 0.60 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 153.7 (1P, s).

Example 29

[0208]


Oxazaphospholidine monomer 4b.

Compound 4b was obtained by using III-b instead of III-a in a similar manner to compound 4a.

^1H NMR (300 MHz, CDCl_3) δ 8.46 (1H, brs), 7.59-7.20 (20H, m), 6.86-6.79 (4H, m), 6.26 (1H, t, $J = 6.8\text{Hz}$), 4.78-4.65 (2H, m), 4.01-3.95 (1H, m), 3.78 (6H, s), 3.55-3.40 (1H, m), 3.42 (1H, dd, $J = 10.5, 2.7\text{Hz}$), 3.40-3.28 (1H, m), 3.22 (1H, dd, $J = 10.5, 3.0\text{Hz}$), 3.19-3.06 (1H, m), 2.16-1.95 (2H, m), 1.90-1.54 (3H, m), 1.49-1.35 (1H, m), 1.43 (3H, s), 1.34-1.17 (2H, m), 0.67 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 156.2 (1P, s).

Example 30

[0209]

Oxazaphospholidine monomer 5a.

Compound 5a was obtained by using "5'-O-(DMTr)-2'-O-methyl-6-N-(benzoyl)adenosine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner


to compound 3a.

^1H NMR (300 MHz, CDCl_3) δ 8.66 (1H, s), 8.13 (1H, s), 8.03 (2H, d, $J = 7.2\text{Hz}$), 7.64-7.16 (23H, m), 6.79 (4H, d, $J = 8.7\text{Hz}$), 6.08 (1H, d, $J = 6.3\text{Hz}$), 4.91-4.81 (1H, m), 4.77-4.69 (1H, m), 4.64-4.57 (1H, m), 4.15-4.10 (1H, m), 3.76 (6H, s), 3.60-3.23 (4H, m), 3.35 (3H, s), 3.14-3.00 (1H, m), 1.90-1.19 (6H, m), 0.62 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 155.8 (1P, s).

Example 31

[0210]

Oxazaphospholidine monomer 5b.




Compound 5b was obtained by using III-b instead of III-a in a similar manner to compound 5a.

^1H NMR (300 MHz, CDCl_3) δ 9.12 (1H, brs), 8.73 (1H, s), 8.24 (1H, s), 8.07-8.01 (2H, m), 7.62-7.17 (22H, m), 6.83-6.77 (4H, m), 6.12 (1H, d, $J = 4.8\text{Hz}$), 4.84-4.73 (2H, m), 4.43 (1H, t, $J = 4.8\text{Hz}$), 4.25-4.19 (1H, m), 3.77 (6H, s), 3.55-3.20 (4H, m), 3.28 (3H, s), 3.16-3.03 (1H, m), 1.90-1.17 (6H, m), 0.65 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 155.0 (1P, s).

Example 32

[0211]

Oxazaphospholidine monomer 6a.

Compound 6a was obtained by using


"5'-O-(DMTr)-2'-O-methyl-4-N-(isobutyryl)cytidine" instead of

"5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

¹H NMR (300 MHz, CDCl₃) δ 8.49 (1H, d, J = 7.2Hz), 7.58-7.20 (19H, m), 6.96 (1H, d, J = 7.2Hz), 6.90-6.82 (4H, m), 5.98 (1H, s), 4.84 (1H, dd, J = 13.1, 7.5Hz), 4.59 (1H, dt, J = 8.3, 4.5Hz), 4.19-4.13 (1H, m), 3.79 (6H, s), 3.78-3.72 (1H, m), 3.63-3.40 (3H, m), 3.55 (3H, s), 3.36-3.24 (1H, m), 3.09-2.95 (1H, m), 2.59 (1H, septet, J = 6.9Hz), 1.85-1.53 (5H, m), 1.48-1.37 (1H, m), 1.24-1.17 (6H, m), 0.59 (3H, s); ³¹P NMR (121.5 MHz, CDCl₃) δ 155.2 (1P, s).

Example 33

[0212]


Oxazaphospholidine monomer 6b.

Compound 6b was obtained by using III-b instead of III-a in a similar manner to compound 6a.

^1H NMR (300 MHz, CDCl_3) δ 8.62 (1H, d, $J = 7.5\text{Hz}$), 7.57-7.23 (19H, m), 7.02 (1H, d, $J = 7.5\text{Hz}$), 6.89-6.81 (4H, m), 5.92 (1H, s), 4.90 (1H, dt, $J = 9.0, 5.7\text{Hz}$), 4.61 (1H, dt, $J = 8.7, 4.8\text{Hz}$), 4.25-4.17 (1H, m), 3.81 (6H, s), 3.67 (1H, d, $J = 4.5\text{Hz}$), 3.62-3.25 (4H, m), 3.38 (3H, s), 3.16-3.02 (1H, m), 2.58 (1H, septet, $J = 6.9\text{Hz}$), 1.87-1.40 (6H, m), 1.26-1.14 (6H, m), 0.64 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 158.2 (1P, s).

Example 34

[0213]

Oxazaphospholidine monomer 7a.

Compound 7a was obtained by using "5'-O-(DMTr)-2'-O-methyl-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" instead of "5'-O-(DMTr)-2'-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar


manner to compound 3a.

^1H NMR (300 MHz, CDCl_3) δ 8.67 (1H, brs), 8.01 (1H, s), 7.56-7.16 (24H, m), 6.83-6.74 (4H, m), 6.08 (1H, d, $J = 6.9\text{Hz}$), 4.85-4.76 (1H, m), 4.84 (2H, t, $J = 6.6\text{Hz}$), 4.65-4.56 (1H, m), 4.59 (2H, brs), 4.48 (1H, dd, $J = 6.6, 5.1\text{Hz}$), 4.09-4.05 (1H, m), 3.75 (6H, s), 3.60-3.42 (2H, m), 3.40-3.26 (2H, m), 3.35 (3H, s), 3.18-3.05 (1H, m), 3.08 (2H, t, $J = 6.6\text{Hz}$), 1.89-1.49 (3H, m), 1.48-1.16 (3H, m), 0.59 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 156.9 (1P, s).

Example 35

[0214]

Oxazaphospholidine monomer 7b.




Compound 7b was obtained by using III-b instead of III-a in a similar manner to compound 7a.

^1H NMR (300 MHz, CDCl_3) δ 8.74 (1H, brs), 8.09 (1H, s), 7.56-6.94 (24H, m), 6.84-6.71 (4H, m), 6.09 (1H, d, $J = 4.8\text{Hz}$), 4.83-4.70 (2H, m), 4.83 (2H, t, $J = 6.6\text{Hz}$), 4.63 (2H, brs), 4.35 (1H, t, $J = 5.0\text{Hz}$), 4.23-4.16 (1H, m), 3.75 (6H, s), 3.58-3.19 (4H, m), 3.32 (3H, s), 3.16-3.04 (1H, m), 3.07 (2H, t, $J = 6.6\text{Hz}$), 1.90-1.55 (3H, m), 1.48-1.15 (3H, m), 0.64 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 154.6 (1P, s).

Example 36

[0215]


Oxazaphospholidine monomer 8a.

Compound 8a was obtained by using "5'-O-(DMTr)-2'-O-(methyl)uridine" instead of "5'-O-(DMTr)-2'-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

^1H NMR (300 MHz, CDCl_3) δ 7.91 (1H, d, $J = 7.8\text{Hz}$), 7.58-7.20 (19H, m), 6.88-6.80 (4H, m), 5.96 (1H, d, $J = 3.3\text{Hz}$), 5.19 (1H, d, $J = 7.8\text{Hz}$), 4.88-4.78 (1H, m), 4.66-4.57 (1H, m), 4.03-3.95 (1H, m), 3.90-3.74 (1H, m), 3.78 (6H, s), 3.77-3.71 (1H, m), 3.58-3.29 (2H, m), 3.45 (3H, s), 3.13-2.82 (2H, m), 1.88-1.53 (3H, m), 1.49-1.16 (3H, m), 0.60 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 155.3 (1P, s).

Example 37

[0216]

Oxazaphospholidine monomer 8b.

Compound 8b was obtained by using III-b instead of III-a in a similar manner to compound 8a.


^1H NMR (300 MHz, CDCl_3) δ 8.10 (1H, d, $J = 8.4\text{Hz}$), 7.58-7.20 (19H, m), 6.87-6.79 (4H, m), 5.89 (1H, d, $J = 1.5\text{Hz}$), 5.21 (1H, d, $J = 8.4\text{Hz}$), 4.92-4.82 (1H, m), 4.73-4.63

(1H, m), 4.15-4.08 (1H, m), 3.89-3.73 (1H, m), 3.78 (6H, s), 3.66-3.62 (1H, m), 3.57-3.27 (2H, m), 3.30 (3H, s), 3.17-2.82 (2H, m), 1.89-1.55 (3H, m), 1.55-1.40 (1H, m), 1.35-1.15 (2H, m), 0.66 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) d 157.5 (1P, s).

Example 38

[0217]

Oxazaphospholidine monomer 9a.




Compound 9a was obtained by using "5'-O-(DMTr)-2'-deoxy-2'-fluoro-6-N-(benzoyl)adenosine" instead of "5'-O-(DMTr)-2'-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

^1H NMR (300 MHz, CDCl_3) d 8.64 (1H, s), 8.14 (1H, s), 8.06-8.01 (2H, m), 7.63-7.07 (23H, m), 6.78-6.70 (4H, m), 6.12 (1H, dd, $J = 18.0, 2.4\text{Hz}$), 5.24-5.01 (2H, m), 4.94-4.84 (1H, m), 4.17-4.06 (1H, m), 3.73 (6H, s), 3.55-3.40 (3H, m), 3.30-3.22 (1H, m), 3.03-2.88 (1H, m), 1.92-1.19 (6H, m), 0.62 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) d 150.5 (1P, d, $J = 7.7\text{Hz}$).

Example 39

[0218]


Oxazaphospholidine monomer 9b.

Compound 9b was obtained by using III-b instead of III-a in a similar manner to compound 9a.

^1H NMR (300 MHz, CDCl_3) δ 9.07 (1H, brs), 8.80 (1H, s), 8.24 (1H, s), 8.08-8.01 (2H, m), 7.66-7.15 (22H, m), 6.81-6.75 (4H, m), 6.14 (1H, dd, $J = 18.0, 1.8\text{Hz}$), 5.16-4.91 (3H, m), 4.28-4.21 (1H, m), 3.76 (6H, s), 3.57-3.11 (5H, m), 1.82-1.16 (6H, m), 0.65 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 157.8 (1P, d, $J = 5.6\text{Hz}$).

Example 40

[0219]

Oxazaphospholidine monomer 10a.

Compound 10a was obtained by using "5'-O-(DMTr)-2'-deoxy-2'-fluoro-4-N-(isobutyryl)cytidine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner


to compound 3a.

^1H NMR (300 MHz, CDCl_3) δ 8.66 (1H, brs), 8.41 (1H, d, $J = 7.5\text{Hz}$), 7.55-7.20 (19H, m), 7.01 (1H, d, $J = 7.5\text{Hz}$), 6.89-6.81 (4H, m), 6.06 (1H, d, $J = 15.9\text{Hz}$), 4.85 (1H, dd, $J = 51.4, 3.9\text{Hz}$), 4.84 (1H, dd, $J = 12.9, 7.5\text{Hz}$), 4.77-4.59 (1H, m), 4.15-4.08 (1H, m), 3.79 (6H, s), 3.63-3.29 (4H, m), 3.10-2.96 (1H, m), 2.65 (1H, septet, $J = 6.9\text{Hz}$), 1.85-1.53 (3H, m), 1.48-1.17 (3H, m), 1.21 (3H, d, $J = 4.8\text{Hz}$), 1.19 (3H, d, $J = 4.8\text{Hz}$), 0.59 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 155.5 (1P, d, $J = 6.6\text{Hz}$).

Example 41

[0220]

Oxazaphospholidine monomer 10b.




Compound 10b was obtained by using III-b instead of III-a in a similar manner to compound 10a.

^1H NMR (300 MHz, CDCl_3) δ 8.53 (1H, d, $J = 7.5\text{Hz}$), 7.57-7.23 (20H, m), 7.10 (1H, d, $J = 7.5\text{Hz}$), 6.89-6.81 (4H, m), 6.10 (1H, d, $J = 15.9\text{Hz}$), 5.00-4.92 (1H, m), 4.84 (1H, dd, $J = 51.5, 3.3\text{Hz}$), 4.75-4.58 (1H, m), 4.24 (1H, d, $J = 9.3\text{Hz}$), 3.81 (6H, s), 3.65-3.39 (3H, m), 3.32-3.06 (2H, m), 2.59 (1H, septet, $J = 6.9\text{Hz}$), 1.88-1.53 (4H, m), 1.49-1.34 (2H, m), 1.27-1.18 (6H, m), 0.65 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 159.0 (1P, d, $J = 4.4$).

Example 42

[0221]

Oxazaphospholidine monomer 11a.


Compound 11a was obtained by using

"5'-O-(DMTr)-2'-deoxy-2'-fluoro-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

¹H NMR (300 MHz, CDCl₃) δ 8.74 (1H, brs), 8.03 (1H, s), 7.55-6.94 (24H, m), 6.80-6.69 (4H, m), 6.21 (1H, dd, J = 14.9, 3.6Hz), 5.34 (1H, dt, J = 52.3, 3.6Hz), 5.01-4.75 (2H, m), 4.84 (1H, t, J = 6.6Hz), 4.62 (2H, brs), 4.15-4.07 (1H, m), 3.73 (6H, s), 3.59-3.29 (4H, m), 3.15-3.00 (1H, m), 3.07 (2H, t, J = 6.6Hz), 1.90-1.49 (3H, m), 1.47-1.12 (3H, m), 0.58 (3H, s); ³¹P NMR (121.5 MHz, CDCl₃) δ 155.6 (1P, d, J = 10.9Hz).

Example 43

[0222]

Oxazaphospholidine monomer 11b.

Compound 11b was obtained by using III-b instead of III-a in a similar manner to


compound 11a.

^1H NMR (300 MHz, CDCl_3) δ 8.81 (1H, brs), 8.06 (1H, s), 7.55-6.95 (24H, m), 6.77-6.69 (4H, m), 6.06 (1H, d, $J = 17.1\text{Hz}$), 5.24-5.08 (1H, m), 5.04-4.80 (2H, m), 4.87 (1H, t, $J = 6.6\text{Hz}$), 4.62 (2H, brs), 4.25-4.19 (1H, m), 3.73 (6H, s), 3.58-3.02 (5H, m), 3.10 (2H, t, $J = 6.6\text{Hz}$), 1.90-1.56 (3H, m), 1.50-1.15 (3H, m), 0.63 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 158.0 (1P, d, $J = 4.4\text{Hz}$).

Example 44

[0223]

Oxazaphospholidine monomer 12a.




Compound 12a was obtained by using "5'-O-(DMTr)-2'-deoxy-2'-fluorouridine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

^1H NMR (300 MHz, CDCl_3) δ 7.85 (1H, d, $J = 8.1\text{Hz}$), 7.58-7.20 (19H, m), 6.87-6.79 (4H, m), 5.98 (1H, d, $J = 16.5\text{Hz}$), 5.23 (1H, d, $J = 8.1\text{Hz}$), 4.86-4.61 (3H, m), 3.99 (1H, d, $J = 6.9\text{Hz}$), 3.76 (6H, d, $J = 3.0\text{Hz}$), 3.56-3.34 (4H, m), 3.10-2.96 (1H, m), 1.88-1.74 (1H, m), 1.72-1.52 (2H, m), 1.48-1.16 (3H, m), 0.61 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 154.3 (1P, d, $J = 8.9\text{Hz}$).

Example 45

[0224]


Oxazaphospholidine monomer 12b.

Compound 12b was obtained by using III-b instead of III-a in a similar manner to compound 12a.

^1H NMR (300 MHz, CDCl_3) δ 8.01 (1H, d, $J = 8.4\text{Hz}$), 7.58-7.20 (19H, m), 6.87-6.79 (4H, m), 6.03 (1H, d, $J = 16.2\text{Hz}$), 5.29 (1H, d, $J = 8.4\text{Hz}$), 4.96 (1H, dd, $J = 13.1, 7.5\text{Hz}$), 4.80-4.54 (2H, m), 4.15 (1H, d, $J = 9.0\text{Hz}$), 3.78 (6H, s), 3.61-3.39 (3H, m), 3.37-3.25 (1H, m), 3.23-3.09 (1H, m), 1.91-1.56 (3H, m), 1.51-1.13 (3H, m), 0.66 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 158.9 (1P, d, $J = 4.4\text{Hz}$).

Example 46

[0225]

Oxazaphospholidine monomer 13a.

Compound 13a was obtained by using "5'-O-(DMTr)-2'-O-TOM-6-N-(acetyl)adenosine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner


to compound 3a.

^1H NMR (300 MHz, CDCl_3) δ 8.82 (1H, brs), 8.49 (1H, s), 8.10 (1H, s), 7.58-7.17 (19H, m), 6.83-6.73 (4H, m), 6.11 (1H, d, $J = 6.6\text{Hz}$), 5.15 (1H, dd, $J = 6.6, 5.4\text{Hz}$), 4.98-4.77 (4H, m), 4.18-4.11 (1H, m), 3.76 (6H, s), 3.59-3.25 (4H, m), 3.16-3.02 (1H, m), 2.62 (3H, s), 1.91-1.53 (3H, m), 1.49-1.18 (3H, m), 0.96-0.80 (3H, m), 0.90 (18H, s), 0.62 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 156.7 (1P, s).

Example 47

[0226]

Oxazaphospholidine monomer 13b.




Compound 13b was obtained by using III-b instead of III-a in a similar manner to compound 13a.

^1H NMR (300 MHz, CDCl_3) δ 8.56 (1H, brs), 8.55 (1H, s), 8.13 (1H, s), 7.57-7.17 (19H, m), 6.82-6.73 (4H, m), 6.16 (1H, d, $J = 5.7\text{Hz}$), 5.06 (1H, t, $J = 5.6\text{Hz}$), 4.93 (1H, d, $J = 5.1\text{Hz}$), 4.83 (1H, d, $J = 5.1\text{Hz}$), 4.81-4.69 (2H, m), 4.27-4.19 (1H, m), 3.76 (6H, s), 3.55-3.40 (2H, m), 3.33-3.16 (2H, m), 3.12-2.97 (1H, m), 2.63 (3H, s), 1.88-1.52 (3H, m), 1.45-1.16 (3H, m), 0.91-0.79 (3H, m), 0.86 (18H, s), 0.64 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 154.8 (1P, s).

Example 48

[0227]


Oxazaphospholidine monomer 14a.

Compound 14a was obtained by using "5'-O-(DMTr)-2'-O-TOM-4-N-(acetyl)cytidine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

¹H NMR (300 MHz, CDCl₃) δ 10.04 (1H, brs), 8.30 (1H, d, J = 7.5Hz), 7.51-7.21 (19H, m), 6.99 (1H, d, J = 7.5Hz), 6.89-6.81 (4H, m), 6.12 (1H, d, J = 3.3Hz), 5.07 (1H, d, J = 4.8Hz), 5.05 (1H, d, J = 4.8Hz), 4.84-4.75 (1H, m), 4.62-4.52 (1H, m), 4.31-4.25 (1H, m), 4.08-4.01 (1H, m), 3.78 (6H, d, J = 3.0Hz), 3.55-3.23 (4H, m), 3.10-2.96 (1H, m), 2.24 (3H, s), 1.84-1.49 (3H, m), 1.46-0.96 (24H, m), 0.58 (3H, s);³¹P NMR (121.5 MHz, CDCl₃) δ 156.5 (1P, s).

Example 49

[0228]

Oxazaphospholidine monomer 14b.


Compound 14b was obtained by using III-b instead of III-a in a similar manner to compound 14a.

¹H NMR (300 MHz, CDCl₃) δ 10.19 (1H, brs), 8.46 (1H, d, J = 7.5Hz), 7.54-7.23 (19H, m), 7.01 (1H, d, J = 7.5Hz), 6.88-6.79 (4H, m), 6.19 (1H, d, J = 1.8Hz), 5.11 (1H, d, J = 4.8Hz), 5.07 (1H, d, J = 4.8Hz), 4.81-4.71 (1H, m), 4.60-4.51 (1H, m), 4.26-4.18 (2H, m), 3.79 (6H, s), 3.63-3.55 (1H, m), 3.48-3.28 (2H, m), 3.21-2.94 (2H, m), 2.26 (3H, s), 1.81-1.49 (3H, m), 1.43-0.96 (24H, m), 0.62 (3H, s); ³¹P NMR (121.5 MHz, CDCl₃) δ 156.4 (1P, s).

Example 50

[0229]

Oxazaphospholidine monomer 15a.




Compound 15a was obtained by using "5'-O-(DMTr)-2'-O-TOM-2-N-(acetyl)guanosine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

¹H NMR (300 MHz, CDCl₃) δ 7.70 (1H, s), 7.63-7.13 (21H, m), 6.84-6.76 (4H, m), 5.77 (1H, d, J = 8.4Hz), 5.41-5.33 (1H, m), 4.90 (2H, s), 4.78-4.68 (2H, m), 3.86 (1H, brs), 3.75 (3H, s), 3.74 (3H, s), 3.56-3.41 (2H, m), 3.32-2.90 (3H, m), 1.92-1.10 (9H, m), 0.97-0.87 (21H, m), 0.52 (3H, s); ³¹P NMR (121.5 MHz, CDCl₃) δ 158.1 (1P, s).

Example 51

[0230]


Oxazaphospholidine monomer 15b.**15b**

Compound 15b was obtained by using III-b instead of III-a in a similar manner to compound 15a.

^1H NMR (300 MHz, CDCl_3) δ 7.77 (1H, s), 7.56-7.15 (21H, m), 6.82-6.75 (4H, m), 5.86 (1H, d, $J = 7.5\text{Hz}$), 5.26-5.17 (1H, m), 4.95 (1H, d, $J = 5.4\text{Hz}$), 4.85 (1H, d, $J = 5.4\text{Hz}$), 4.78-4.71 (1H, m), 4.59-4.49 (1H, m), 4.10-4.05 (1H, m), 3.74 (6H, s), 3.52-3.37 (2H, m), 3.30-3.18 (1H, m), 3.11-2.85 (2H, m), 1.85-1.15 (9H, m), 0.93-0.84 (21H, m), 0.62 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 152.3 (1P, s).

Example 52

[0231]

Oxazaphospholidine monomer 16a.**16a**

Compound 16a was obtained by using "5'-O-(DMTr)-2'-O-TOM-uridine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.


^1H NMR (300 MHz, CDCl_3) δ 7.76 (1H, d, $J = 8.1\text{Hz}$), 7.55-7.18 (20H, m), 6.88-6.80 (4H, m), 6.11 (1H, d, $J = 6.0\text{Hz}$), 5.32 (1H, d, $J = 8.1\text{Hz}$), 4.99 (1H, d, $J = 5.1\text{Hz}$), 4.93

(1H, d, J = 5.1Hz), 4.84-4.75 (1H, m), 4.54-4.46 (1H, m), 4.38 (1H, t, J = 5.7Hz), 3.87-3.83 (1H, m), 3.78 (3H, s), 3.77 (3H, s), 3.56-3.42 (1H, m), 3.39-3.28 (1H, m), 3.36 (1H, dd, J = 11.0, 2.7Hz), 3.25 (1H, dd, J = 11.0, 2.7Hz), 3.16-3.03 (1H, m), 1.88-1.12 (6H, m), 1.08-0.97 (21H, m), 0.59 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 156.6 (1P, s).

Example 53

[0232]

Oxazaphospholidine monomer 16b.




Compound 16b was obtained by using III-b instead of III-a in a similar manner to compound 16a.

^1H NMR (600 MHz, CDCl_3) δ 7.87 (1H, d, J = 7.8Hz), 7.52-7.48 (4H, m), 7.38-7.21 (16H, m), 6.83-6.79 (4H, m), 6.14 (1H, d, J = 4.8Hz), 5.33 (1H, d, J = 7.8Hz), 4.99 (1H, d, J = 5.4Hz), 4.89 (1H, d, J = 5.4Hz), 4.67 (1H, dd, J = 13.8, 7.2Hz), 4.52 (1H, dt, J = 10.4, 4.8Hz), 4.31 (1H, t, J = 4.8Hz), 4.06-4.03 (1H, m), 3.78 (3H, s), 3.77 (3H, s), 3.47 (1H, dd, J = 10.4, 2.4Hz), 3.47-3.39 (1H, m), 3.22-3.17 (2H, m), 3.00 (1H, ddd, J = 19.5, 10.4, 4.8Hz), 1.82-1.74 (1H, m), 1.68-1.58 (1H, m), 1.56 (1H, dd, J = 14.4, 8.4Hz), 1.38 (1H, dd, J = 14.4, 7.2Hz), 1.31-1.25 (1H, m), 1.26-1.17 (1H, m), 1.08-0.98 (21H, m), 0.63 (3H, s); ^{31}P NMR (243.0 MHz, CDCl_3) δ 154.3 (1P, s).

Example 54

[0233]

Oxazaphospholidine monomer 17a.**17a**

Compound 17a was obtained by using


"5'-O-(DMTr)-2'-O,4'-C-methylene-6-N-(benzoyl)adenosine" instead of

"5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

^1H NMR (300 MHz, CDCl_3) δ 9.10 (1H, brs), 8.76 (1H, s), 8.32 (1H, s), 8.04 (2H, d, $J = 7.2\text{Hz}$), 7.64-7.18 (22H, m), 6.84 (4H, d, $J = 8.7\text{Hz}$), 6.10 (1H, s), 4.76 (1H, d, $J = 6.9\text{Hz}$), 4.58 (1H, s), 4.61-4.51 (1H, m), 3.91 (1H, d, $J = 7.8\text{Hz}$), 3.77 (1H, d, $J = 7.8\text{Hz}$), 3.75 (6H, s), 3.50 (1H, s), 3.47-3.33 (1H, m), 3.31-3.19 (1H, m), 3.03-2.88 (1H, m), 1.84-1.09 (6H, m), 0.51 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 152.9 (1P, s).

Example 55

[0234]

Oxazaphospholidine monomer 17b.**17b**


Compound 17b was obtained by using III-b instead of III-a in a similar manner to compound 17a.

^1H NMR (300 MHz, CDCl_3) δ 8.81 (1H, s), 8.30 (1H, s), 8.07-8.00 (2H, m), 7.64-7.17 (22H, m), 6.86-6.79 (4H, m), 6.12 (1H, s), 4.81-4.72 (1H, m), 4.62 (1H, d, $J = 7.2\text{Hz}$), 4.57 (1H, s), 3.94 (1H, d, $J = 7.8\text{Hz}$), 3.89 (1H, d, $J = 7.8\text{Hz}$), 3.77 (6H, s), 3.48 (2H, s), 3.46-3.32 (1H, m), 3.24-3.13 (1H, m), 3.10-2.97 (1H, m), 1.84-1.49 (3H, m), 1.42-1.09 (3H, m), 0.58 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 157.3 (1P, s).

Example 56

[0235]

Oxazaphospholidine monomer 18a.




Compound 18a was obtained by using "5'-O-(DMTr)-2'-O,4'-C-methylene-4-N-(isobutyryl)-5-methylcytidine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

^1H NMR (300 MHz, CDCl_3) δ 7.88 (1H, brs), 7.58-7.18 (20H, m), 6.88-6.80 (4H, m), 5.65 (1H, s), 4.69-4.60 (1H, m), 4.52 (1H, d, $J = 6.6\text{Hz}$), 4.49 (1H, s), 3.81-3.74 (1H, m), 3.75 (3H, s), 3.73 (3H, s), 3.64 (1H, d, $J = 8.1\text{Hz}$), 3.56 (1H, d, $J = 11.1\text{Hz}$), 3.53 (1H, d, $J = 8.1\text{Hz}$), 3.46 (1H, d, $J = 11.1\text{Hz}$), 3.56-3.40 (1H, m), 3.32-3.20 (1H, m), 3.14-3.00 (1H, m), 1.85-1.12 (6H, m), 1.60 (3H, s), 1.19 (6H, d, $J = 6.9\text{Hz}$), 0.55 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 155.9 (1P, s).

Example 57

[0236]


Oxazaphospholidine monomer 18b.

Compound 18b was obtained by using III-b instead of III-a in a similar manner to compound 18a.

^1H NMR (300 MHz, CDCl_3) δ 7.86 (1H, brs), 7.56-7.19 (20H, m), 6.88-6.79 (4H, m), 5.69 (1H, s), 4.86-4.76 (1H, m), 4.46 (1H, s), 4.45 (1H, d, $J = 7.5\text{Hz}$), 3.80-3.75 (1H, m), 3.79 (6H, s), 3.74 (1H, d, $J = 8.1\text{Hz}$), 3.69 (1H, d, $J = 8.1\text{Hz}$), 3.51 (1H, d, $J = 11.1\text{Hz}$), 3.44-3.30 (1H, m), 3.39 (1H, d, $J = 11.1\text{Hz}$), 3.29-3.17 (1H, m), 3.11-2.97 (1H, m), 1.86-1.52 (3H, m), 1.64 (3H, s), 1.45-1.10 (3H, m), 1.21 (6H, d, $J = 6.6\text{Hz}$), 0.62 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 158.2 (1P, s).

Example 58

[0237]

Oxazaphospholidine monomer 19a.

Compound 19a was obtained by using
 "5'-O-(DMTr)-2'-O,4'-C-methylene-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine"


instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

^1H NMR (300 MHz, CDCl_3) δ 8.71 (1H, brs), 8.16 (1H, s), 7.50-7.17 (21H, m), 7.09-7.01 (3H, m), 6.86-6.79 (4H, m), 6.03 (1H, s), 4.84 (2H, t, $J = 6.6\text{Hz}$), 4.72 (2H, s), 4.68 (1H, d, $J = 7.2\text{Hz}$), 4.55-4.46 (1H, m), 4.50 (1H, s), 3.90 (1H, d, $J = 7.8\text{Hz}$), 3.77 (1H, d, $J = 7.8\text{Hz}$), 3.75 (6H, s), 3.51 (1H, d, $J = 10.8\text{Hz}$), 3.47 (1H, d, $J = 10.8\text{Hz}$), 3.45-3.21 (2H, m), 3.08 (2H, t, $J = 6.6\text{Hz}$), 3.03-2.89 (1H, m), 1.80-1.08 (6H, m), 0.47 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 153.2 (1P, s).

Example 59

[0238]

Oxazaphospholidine monomer 19b.



19b

Compound 19b was obtained by using III-b instead of III-a in a similar manner to compound 19a.

^1H NMR (300 MHz, CDCl_3) δ 8.86 (1H, brs), 8.13 (1H, s), 7.55-7.17 (21H, m), 7.08-6.98 (3H, m), 6.95-6.78 (4H, m), 6.01 (1H, s), 4.86 (2H, t, $J = 6.6\text{Hz}$), 4.82-4.73 (1H, m), 4.70 (2H, s), 4.64 (1H, d, $J = 7.5\text{Hz}$), 4.49 (1H, s), 3.94 (1H, d, $J = 7.8\text{Hz}$), 3.89 (1H, d, $J = 7.8\text{Hz}$), 3.77 (6H, s), 3.46 (2H, s), 3.45-3.30 (1H, m), 3.24-3.12 (1H, m), 3.09 (2H, t, $J = 6.6\text{Hz}$), 3.09-2.96 (1H, m), 1.81-1.50 (3H, m), 1.41-1.06 (3H, m), 0.58 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 157.4 (1P, s).

Example 60


[0239]

^1H NMR (300 MHz, CDCl_3) δ 7.69 (1H, s), 7.56-7.19 (20H, m), 6.88-6.79 (4H, m), 5.66 (1H, s), 4.87-4.77 (1H, m), 4.47 (1H, d, $J = 7.8\text{Hz}$), 4.40 (1H, s), 3.78 (6H, s), 3.74 (1H, d, $J = 7.8\text{Hz}$), 3.68 (1H, d, $J = 7.8\text{Hz}$), 3.50 (1H, d, $J = 10.8\text{Hz}$), 3.46-3.32 (1H, m), 3.39 (1H, d, $J = 10.8\text{Hz}$), 3.30-3.19 (1H, m), 3.12-2.98 (1H, m), 1.85-1.56 (3H, m), 1.59 (3H, s), 1.46-1.12 (3H, m), 0.63 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 158.1 (1P, s).

Example 62

[0241]

Oxazaphospholidine monomer 21a.




Compound 21a was obtained by using "5'-O-(DMTr)-2'-O-methoxyethyl-5-methyluridine" instead of "5'-O-(DMTr)-2-N-(phenoxyacetyl)-6-O-(cyanoethyl)guanosine" in a similar manner to compound 3a.

^1H NMR (300 MHz, CDCl_3) δ 7.62-7.18 (21H, m), 6.84 (4H, d, $J = 8.7\text{Hz}$), 6.07 (1H, d, $J = 5.7\text{Hz}$), 4.86-4.76 (1H, m), 4.63-4.54 (1H, m), 4.20 (1H, t, $J = 5.4\text{Hz}$), 3.95-3.89 (1H, m), 3.78 (6H, s), 3.78-3.71 (2H, m), 3.60-3.48 (2H, m), 3.44-3.02 (5H, m), 3.31 (3H, s), 1.88-1.15 (6H, m), 1.35 (3H, s), 0.58 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 156.3 (1P, s).

Example 63

[0242]


Oxazaphospholidine monomer 21b.

Compound 21b was obtained by using III-b instead of III-a in a similar manner to compound 21a.

^1H NMR (300 MHz, CDCl_3) δ 7.71 (1H, d, $J = 1.2\text{Hz}$), 7.55-7.22 (20H, m), 6.86-6.78 (4H, m), 5.99 (1H, d, $J = 3.9\text{Hz}$), 4.78-4.62 (2H, m), 4.13-4.08 (1H, m), 4.07-4.02 (1H, m), 3.77 (6H, s), 3.77-3.70 (1H, m), 3.65-3.56 (1H, m), 3.52-3.36 (4H, m), 3.33-3.14 (2H, m), 3.29 (3H, s), 3.08-2.94 (1H, m), 1.86-1.72 (1H, m), 1.71-1.55 (2H, m), 1.30 (3H, d, $J = 1.2\text{Hz}$), 1.47-1.16 (3H, m), 0.64 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 155.6 (1P, s).

Example 64

[0243]

Oxazaphospholidine monomer 22a.

Compound 22a was obtained by using VII-a instead of III-a in a similar manner to compound 4a.


^1H NMR (300 MHz, CDCl_3) δ 7.57 (1H, d, $J = 0.9\text{Hz}$), 7.37-6.94 (20H, m), 6.87-6.78 (4H, m), 6.48 (1H, dd, $J = 8.6, 5.7\text{Hz}$), 5.42 (1H, dd, $J = 11.0, 5.1\text{Hz}$), 4.81-4.71 (1H,

m), 4.02 (1H, d, $J = 11.0\text{Hz}$), 3.83 (1H, d, $J = 2.1\text{Hz}$), 3.79 (6H, s), 3.61-3.41 (2H, m), 3.24-3.09 (1H, m), 3.16 (1H, dd, $J = 10.8, 2.4\text{Hz}$), 3.02 (1H, dd, $J = 10.8, 2.4\text{Hz}$), 2.54-2.44 (1H, m), 2.34-2.22 (1H, m), 1.94-1.79 (1H, m), 1.74-1.56 (1H, m), 1.38 (3H, s), 1.38-1.28 (2H, m); ^{31}P NMR (121.5 MHz, CDCl_3) d 160.9 (1P, s).

Example 65

[0244]

Oxazaphospholidine monomer 22b.




Compound 22b was obtained by using VII-b instead of VII-a in a similar manner to compound 22a.

^1H NMR (300 MHz, CDCl_3) d 7.57 (1H, d, $J = 1.5\text{Hz}$), 7.43-7.11 (20H, m), 6.85-6.78 (4H, m), 6.48 (1H, dd, $J = 7.5, 5.7\text{Hz}$), 5.58 (1H, dd, $J = 11.4, 5.1\text{Hz}$), 4.82-4.73 (1H, m), 4.17-4.02 (2H, m), 3.78 (6H, s), 3.56-3.40 (3H, m), 3.32 (1H, dd, $J = 10.7, 2.4\text{Hz}$), 3.22-3.07 (1H, m), 2.26-2.04 (2H, m), 1.95-1.81 (1H, m), 1.74-1.56 (1H, m), 1.40 (3H, d, $J = 1.5\text{Hz}$), 1.44-1.34 (2H, m); ^{31}P NMR (121.5 MHz, CDCl_3) d 162.2 (1P, s).

Example 66

[0245]

Oxazaphospholidine monomer 23a.




Compound 23a was obtained by using IX-a instead of III-a in a similar manner to compound 4a.

^1H NMR (300 MHz, CDCl_3) δ 9.22 (1H, brs), 8.05-7.99 (2H, m), 7.52 (1H, d, J = 1.2Hz), 7.41-7.19 (11H, m), 6.87-6.79 (4H, m), 6.37 (1H, dd, J = 8.4, 5.7Hz), 4.88-4.75 (2H, m), 3.86-3.80 (1H, m), 3.79 (6H, s), 3.64-3.49 (2H, m), 3.27-3.12 (3H, m), 2.97 (2H, d, J = 6.6Hz), 2.51-2.41 (1H, m), 2.33-2.20 (1H, m), 2.03-1.75 (2H, m), 1.72-1.59 (1H, m), 1.46-1.36 (1H, m), 1.40 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 157.5 (1P, s).

Example 67

[0246]

Oxazaphospholidine monomer 23b.




23b

Compound 23b was obtained by using IX-b instead of IX-a in a similar manner to compound 23a.

^1H NMR (300 MHz, CDCl_3) δ 8.67 (1H, brs), 8.18-8.11 (2H, m), 7.57 (1H, d, J = 1.2Hz), 7.47-7.22 (11H, m), 6.86-6.79 (4H, m), 6.29 (1H, t, J = 6.6Hz), 4.87 (1H, dt, J = 7.5, 5.7Hz), 4.80-4.72 (1H, m), 4.11-4.05 (1H, m), 3.79 (6H, s), 3.67-3.47 (2H, m), 3.43 (1H, dd, J = 10.8, 2.7Hz), 3.27 (1H, dd, J = 10.8, 2.4Hz), 3.25-3.13 (1H, m), 3.07-2.99 (2H, m), 2.19-2.12 (2H, m), 2.03-1.62 (3H, m), 1.46-1.30 (1H, m), 1.41 (3H, s); ^{31}P NMR (121.5 MHz, CDCl_3) δ 158.1 (1P, s).

Example 68

[0247]

Oxazaphospholidine monomer 24a.

Compound 24a was obtained by using XIII-a instead of III-a in a similar manner to compound 4a.

^1H NMR (600 MHz, CDCl_3) δ 7.76 (2H, d, $J = 9.0\text{Hz}$), 7.62 (1H, d, $J = 1.2\text{Hz}$), 7.40 (2H, d, $J = 7.2\text{Hz}$), 7.32-7.23 (10H, m), 6.85 (4H, d, $J = 8.4\text{Hz}$), 6.41 (1H, dd, $J = 8.4$, 5.4Hz), 4.94 (1H, dd, $J = 12.3$, 5.4Hz), 4.84-4.79 (1H, m), 4.03-4.01 (1H, m), 3.79 (6H, s), 3.59-3.53 (1H, m), 3.52-3.44 (2H, m), 3.41 (1H, dd, $J = 14.7$, 7.2Hz), 3.37-3.30 (2H, m), 3.13 (1H, ddd, $J = 19.3$, 10.3 , 4.1Hz), 2.50-2.44 (1H, m), 2.39 (3H, s), 2.35-2.29 (1H, m), 1.91-1.72 (2H, m), 1.64-1.59 (1H, m), 1.40 (3H, s), 1.12-1.05 (1H, m); ^{31}P NMR (243.0 MHz, CDCl_3) δ 154.2 (1P, s).

[0248] General procedure for the synthesis of chiral-oligos:

The automated solid-phase synthesis of chiral-oligos were performed according to the cycles shown in Table 1. After the synthesis, the resin was treated with a 25% NH_3 aqueous solution (1 mL) for 12 h at 55 degrees C. The mixture was cooled to room temperature and the resin was removed by membrane filtration. The filtrate was concentrated to dryness under reduced pressure. The residue was dissolved in H_2O (3 mL) and analyzed by RP-UPLC-MS with a linear gradient of acetonitrile (0-50%/30 min) in 0.1 M triethylammonium acetate buffer (pH 7.0) at 50 degrees C at a rate of 0.3 mL/min.


[0249]

Table.1

step	operation	reagents and solvent	volume	waiting
1	detritylation	3% DCA/DCM	1.6 mL	20 s
2	coupling	0.1M monomer/MeCN + 1M	0.5 mL	5 min
3	capping	Ac ₂ O/THF-pyridine + 16% /THF	0.5 mL	30 s
4	oxidation / urization	0.5M CSO/MeCN or 0.1M MeCN	0.5 mL	90 s

Comparison Example 1

[0250]



[0251] The above Compound 25, which represents a conventional monomer, was used to produce oligos. Figure 2 shows a chart of products obtained through Comparison Example 1.

[0252] Analysis


The monomers of the working examples were chemically stable. The isolate yield of the monomers were more than 80 %, which was higher than that of conventional method.

[0253] We synthesized oligonucleotide derivatives using the chiral reagents of the above working examples based on the second general procedure and monomers of the above working examples based on the first general procedure. As shown in Figure 2, the conventional monomer causes incomplete de-protection products, side products and failure sequences. On the other hand, the method of the invention causes little incomplete de-protection products and little side products even though it causes failure sequences as shown in Figure 1. It is obvious that the method of the invention can lessen the incomplete de-protection products and side products. It was easy to isolate the targeted oligonucleotide derivatives because the present invention can lessen undesirable products.


Claims

[Claim 1]


A chiral reagent or a salt thereof, the chiral reagent having following chemical formula (I),




wherein G^1 and G^2 are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, a group of formula (II), (III) or (V), or both G^1 and G^2 taken together to form a group of formula (IV),




wherein G^{21} to G^{23} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group,



wherein G^{31} to G^{33} are independently C_{1-4} alkyl group, C_{1-4} alkoxy group, C_{6-14} aryl group, C_{7-14} aralkyl group, C_{1-4} alkyl C_{6-14} aryl group, C_{1-4} alkoxy C_{6-14} aryl group, or C_{6-14} aryl C_{1-4} alkyl group,




wherein G^{41} to G^{46} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group,
 G^3 and G^4 are independently a hydrogen atom, C_{1-3} alkyl group, C_{6-14} aryl group, or both G^3 and G^4 taken together to form a heteroatom-containing ring that has 3 to 16 carbon atoms,



wherein G^{51} to G^{53} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, C_{1-3} alkyl group or C_{1-3} alkyloxy group.

[Claim 2]

The chiral reagent or a salt thereof in accordance with claim 1, wherein the chiral reagent has following chemical formula (I').



[Claim 3]

The chiral reagent or a salt thereof in accordance with claim 2, wherein each of G^1 and G^2 is a group of formula (II), wherein G^{21} to G^{23} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group.

[Claim 4]

The chiral reagent or a salt thereof in accordance with claim 2, wherein each of G^1 and G^2 is a group of formula (II), wherein each of G^{21} to G^{23} is a hydrogen atom.

[Claim 5]

The chiral reagent or a salt thereof in accordance with claim 2, wherein G^1 is a hydrogen atom, and G^2 is a group of formula (II), wherein G^{21} to G^{23} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group.

[Claim 6]

The chiral reagent or a salt thereof in accordance with claim 2, wherein G^1 is a hydrogen atom and G^2 is a group of formula (II), wherein each of G^{21} and G^{22} is a hydrogen atom and G^{23} is a nitro group.



[Claim 7]

The chiral reagent or a salt thereof in accordance with claim 2, wherein G^1 is a hydrogen atom, and G^2 is a group of formula (III), wherein G^{31} to G^{33} are independently C_{1-4} alkyl group, C_{6-14} aryl group, C_{7-14} aralkyl group, C_{1-4} alkyl C_{6-14} aryl group, C_{1-4} alkoxy C_{6-14} aryl group, or C_{6-14} aryl C_{1-4} alkyl group.


[Claim 8]

The chiral reagent or a salt thereof in accordance with claim 2, wherein G^1 is a hydrogen atom, and G^2 is a group of formula (III), wherein G^{31} to G^{33} are independently C_{1-4} alkyl group, C_6 aryl group, C_{7-10} aralkyl group, C_{1-4} alkyl C_6 aryl group, C_{1-4} alkoxy C_6 aryl group, or C_6 aryl C_{1-4} alkyl group.


- [Claim 9] The chiral reagent or a salt thereof in accordance with claim 2, wherein G^1 is a hydrogen atom and G^2 is a group of formula (III), wherein G^{31} to G^{33} are independently C_{1-4} alkyl group, or C_6 aryl group.
- [Claim 10] The chiral reagent or a salt thereof in accordance with claim 2, wherein G^1 is a hydrogen atom and G^2 is a group of formula (III), wherein G^{31} to G^{33} are independently C_{1-4} alkyl group.
- [Claim 11] The chiral reagent or a salt thereof in accordance with claim 2, wherein G^1 is a hydrogen atom and G^2 is a group of formula (III), wherein G^{31} and G^{33} are C_6 aryl group and G^{32} is C_{1-4} alkyl group.
- [Claim 12] The chiral reagent or a salt thereof in accordance with claim 2, wherein G^1 and G^2 taken together to form a group of formula (IV), wherein G^{41} to G^{46} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group.
- [Claim 13] The chiral reagent or a salt thereof in accordance with claim 2, wherein G^1 and G^2 taken together to form a group of formula (IV), wherein each of G^{41} to G^{46} is a hydrogen atom.
- [Claim 14] The chiral reagent or a salt thereof in accordance with claim 2, wherein G^1 is a hydrogen atom and G^2 is a group of formula (V), wherein each of G^{51} to G^{53} are independently a hydrogen atom, a nitro group, a methyl group, or a methoxy group.
- [Claim 15] The chiral reagent or a salt thereof in accordance with claim 2, wherein G^1 is a hydrogen atom and G^2 is a group of formula (V), wherein each of G^{51} and G^{53} is a hydrogen atom and G^{52} is a 4-methyl group.
- [Claim 16] The chiral reagent or a salt thereof in accordance with claim 2, wherein the chiral reagent is represented by III-a, III-b, V-a, VII-a, VII-b, IX-a, IX-b, XI-a, XIII-a or XIII-b:
 (S)-2-(Methyldiphenylsilyl)-1-((S)-pyrrolidin-2-yl)ethanol (III-a)
 (R)-2-(Methyldiphenylsilyl)-1-((R)-1-pyrrolidin-2-yl)ethanol (III-b)
 (S)-2-(Trimethylsilyl)-1-((S)-1-pyrrolidin-2-yl)ethanol (V-a)
 (R)-2,2-Diphenyl-1-((S)-pyrrolidin-2-yl)ethanol (VII-a)
 (S)-2,2-Diphenyl-1-((R)-pyrrolidin-2-yl)ethanol (VII-b)
 (R)-2-(4-Nitrophenyl)-1-((S)-pyrrolidin-2-yl)ethanol (IX-a)
 (S)-2-(4-Nitrophenyl)-1-((R)-pyrrolidin-2-yl)ethanol (IX-b)
 (R)-(9H-Fluorene-9-yl)((S)-pyrrolidin-2-yl)methanol (XI-a)
 (S)-2-Tosyl-1-((S)-1-tritylpyrrolidin-2-yl)ethanol (XIII-a)
 (R)-2-Tosyl-1-((R)-1-tritylpyrrolidin-2-yl)ethanol (XIII-b)
- [Claim 17] A nucleoside 3'-phosphoramidite derivative which is represented by formula (Va) or (Vb),




wherein G^1 and G^2 are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, a group of formula (II), (III) or (V), both G^1 and G^2 taken together to form a group of formula (IV),




wherein G^{21} to G^{23} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group,



wherein G^{31} to G^{33} are independently C_{1-4} alkyl group, C_{1-4} alkoxy group, C_{6-14} aryl group, C_{7-14} aralkyl group, C_{1-4} alkyl C_{6-14} aryl group, C_{1-4} alkoxy C_{6-14} aryl group, or C_{6-14} aryl C_{1-4} alkyl group,



wherein G^{41} to G^{46} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group,



wherein G^{51} to G^{53} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, C_{1-3} alkyl group or C_{1-3} alkyloxy group, G^3 and G^4 are independently a hydrogen atom, C_{1-3} alkyl group, C_{6-14} aryl group, or both G^3 and G^4 taken together to form a heteroatom-containing ring that has 3 to 16 carbon atoms.

G^5 is a protective group of a hydroxyl group,

R^2 is hydrogen, -OH, -SH, -NR^dR^d, -N₃, halogen, alkyl, alkenyl, alkynyl, alkyl-Y¹-, alkenyl-Y¹-, alkynyl-Y¹-, aryl-Y¹-, heteroaryl-Y¹-, -OR^b, or -SR^b, wherein R^b is a blocking moiety,

Y¹ is O, NR^d, S, or Se,


R^d is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, -P(O)(R^e)₂, or -HP(O)(R^e),

R^e is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y²-, alkenyl-Y²-, alkynyl-Y²-, aryl-Y²-, or heteroaryl-Y²-, or a cation which is Na⁺, Li⁺, or K⁺,


Y² is O, NR^d, or S,

R³ is a group represented by -CH₂-, -(CH₂)₂-, -CH₂NH-, or -CH₂N(CH₃)-, and


Bs is a group selected from the groups represented by following formula (VI) to (XI) or derivatives thereof.




(VI)




(VII)




(VIII)



(IX)




(X)



(XI)



[Claim 18]




The nucleoside 3'-phosphoramidite derivative in accordance with claim 17, wherein the nucleoside 3'-phosphoramidite derivative is represented by formula (Va') or (Vb').









[Claim 19]




The nucleoside 3'-phosphoramidite derivative in accordance with claim 17, wherein the nucleoside 3'-phosphoramidite derivative is represented by formula 1a, 1b, 2a, 2b, 3a, 3b, 4a, 4b, 5a, 5b, 6a, 6b, 7a, 7b, 8a, 8b, 9a, 9b, 10a, 10b, 11a, 11b, 12a, 12b, 13a, 13b, 14a, 14b, 15a, 15b, 16a, 16b, 17a, 17b, 18a, 18b, 19a, 19b, 20a, 20b, 21a, 21b, 22a, 22b, 23a, 23b, or 24a.












**3b****4a****4b**
















11a









11b









12a




**12b****13a****13b**



















**23a****23b****24a**

wherein DMTr represents a 4,4'-dimethoxytrityl group and TOM represents a triisopropylsiloxymethyl group.

[Claim 20]


A method for synthesis of stereocontrolled phosphorus atom-modified oligonucleotide derivatives comprising steps of:

reacting a molecule comprising an achiral H-phosphonate moiety, a chiral reagent or a salt thereof to form a monomer of a nucleoside 3'-phosphoramidite derivative,
 reacting the monomer and a nucleoside to form a condensed in-


intermediate; and

converting the condensed intermediate to the nucleic acid comprising a chiral X-phosphonate moiety,


wherein the chiral reagent has following chemical formula (I),




wherein G^1 and G^2 are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, a group of formula (II), (III) or (V), or both G^1 and G^2 taken together to form a group of formula (IV),




wherein G^{21} to G^{23} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group,



wherein G^{31} to G^{33} are independently C_{1-4} alkyl group or C_{6-14} aryl group, C_{1-4} alkoxy group, C_{6-14} aryl group, C_{7-14} aralkyl group, C_{1-4} alkyl C_{6-14} aryl group, C_{1-4} alkoxy C_{6-14} aryl group, or C_{6-14} aryl C_{1-4} alkyl group,



wherein G^{41} to G^{46} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group or C_{1-3} alkyl group,




wherein G^{51} to G^{53} are independently a hydrogen atom, a nitro group, a halogen atom, a cyano group, C_{1-3} alkyl group or C_{1-3} alkyloxy group, and

G^3 and G^4 are independently a hydrogen atom, C_{1-3} alkyl group, C_{6-14} aryl group, or both G^3 and G^4 taken together to form a heteroatom-containing ring that has 3 to 16 carbon atoms.

[Claim 21]

The method for synthesis of stereocontrolled phosphorus atom-modified oligonucleoside derivatives in accordance with claim 20, wherein the wherein the chiral reagent has following chemical formula (I').



[Claim 22]

The method for synthesis of a stereocontrolled phosphorus atom-modified oligonucleotide derivative in accordance with claim 20, wherein the chiral reagent is represented by III-a, III-b, V-a, VII-a, VII-b, IX-a, IX-b, XI-a, XIII-a and XIII-b:

(S)-2-(Methyldiphenylsilyl)-1-((S)-pyrrolidin-2-yl)ethanol (III-a)

(R)-2-(Methyldiphenylsilyl)-1-((R)-1-pyrrolidin-2-yl)ethanol (III-b)

(S)-2-(Trimethylsilyl)-1-((S)-1-pyrrolidin-2-yl)ethanol (V-a)

(R)-2,2-Diphenyl-1-((S)-pyrrolidin-2-yl)ethanol (VII-a)

(S)-2,2-Diphenyl-1-((R)-pyrrolidin-2-yl)ethanol (VII-b)

(R)-2-(4-Nitrophenyl)-1-((S)-pyrrolidin-2-yl)ethanol (IX-a)

(S)-2-(4-Nitrophenyl)-1-((R)-pyrrolidin-2-yl)ethanol (IX-b)

(R)-(9H-Fluorene-9-yl)((S)-pyrrolidin-2-yl)methanol (XI-a)

(S)-2-Tosyl-1-((S)-1-tritylpyrrolidin-2-yl)ethanol (XIII-a)


(R)-2-Tosyl-1-((R)-1-tritylpyrrolidin-2-yl)ethanol (XIII-b)

[Claim 23]

A method for synthesis of stereocontrolled phosphorus atom-modified oligonucleotide derivatives comprising steps of:


reacting a nucleoside 3'-phosphoramidite derivative which is represented by formula (Va) or (Vb), with an activating reagent and a nu-

cleoside to form a condensed intermediate; and converting the condensed intermediate to the nucleic acid comprising a chiral X-phosphonate moiety.






[Claim 24]




The method for synthesis of stereocontrolled phosphorus atom-modified oligonucleotide derivatives in accordance with claim 23, wherein the nucleoside 3'-phosphoramidite derivative is represented by formula (Va') or (Vb').









[Claim 25]




The method for synthesis of stereocontrolled phosphorus atom-modified oligonucleotide derivatives in accordance with claim 23, wherein the nucleoside 3'-phosphoramidite derivative is represented by formula 1a, 1b, 2a, 2b, 3a, 3b, 4a, 4b, 5a, 5b, 6a, 6b, 7a, 7b, 8a, 8b, 9a, 9b, 10a, 10b, 11a, 11b, 12a, 12b, 13a, 13b, 14a, 14b, 15a, 15b, 16a, 16b, 17a, 17b, 18a, 18b, 19a, 19b, 20a, 20b, 21a, 21b, 22a, 22b, 23a, 23b, or 24a,

























10a




10b




11a


**11b****12a****12b**
















19a








19b



20a

**20b****21a****21b**



**23b****24a**

wherein DMTr represents a 4,4'-dimethoxytrityl group and TOM represents a triisopropylsiloxymethyl group.